{
   "Roivant Sciences": [
      {
         "Developer ": {
            " Researcher": "Roivant Sciences"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II study started in April 2020",
         "Product Description": "Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal",
         "Clinical Trials for COVID-19": "NCT04351243",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/14/2020"
      }
   ],
   "Generation Bio / Vir Biotechnology": [
      {
         "Developer ": {
            " Researcher": "Generation Bio / Vir Biotechnology"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Non-viral gene therapy to produce monoclonal antibodies",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Edesa Biotech/ Light Chain Bioscience (NovImmune)": [
      {
         "Developer ": {
            " Researcher": "Edesa Biotech/ Light Chain Bioscience (NovImmune)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I/II not yet recruiting July 2020",
         "Product Description": "EB05, non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) ",
         "Clinical Trials for COVID-19": "NCT04401475",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "ARDS"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "University of Hong Kong (BMS)": [
      {
         "Developer ": {
            " Researcher": "University of Hong Kong (BMS)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II study not yet recruiting",
         "Product Description": "Opdivo (nivolumab), PD-1 blocking antibody",
         "Clinical Trials for COVID-19": "NCT04356508\n\nNCT04333914 ",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2014, approved to treat melanoma and squamous non-small cell lung cancer",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/27/2020"
      }
   ],
   "Atreca / BeiGene / IGM Biosciences": [
      {
         "Developer ": {
            " Researcher": "Atreca / BeiGene / IGM Biosciences"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Novel IgM and IgA antibodies \n",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "Ablexis / AlivaMab Discovery Services / Berkeley Lights Collaborate": [
      {
         "Developer ": {
            " Researcher": "Ablexis / AlivaMab Discovery Services / Berkeley Lights Collaborate"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibodies",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A\n",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      }
   ],
   "Implicit Bioscience": [
      {
         "Developer ": {
            " Researcher": "Implicit Bioscience"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Expanded access protocols",
         "Product Description": "IC14, recombinant chimeric anti-CD14 monoclonal antibody",
         "Clinical Trials for COVID-19": "NCT04346277",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Acute Respiratory Distress Syndrome"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Numerous trials with Chinese research sponsors; Roche": [
      {
         "Developer ": {
            " Researcher": "Numerous trials with Chinese research sponsors; Roche"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II/III studies recruiting April 2020",
         "Product Description": "Avastin (bevacizumab), vascular endothelial growth factor inhibitor",
         "Clinical Trials for COVID-19": "NCT04275414\n\nNCT04305106\n\nNCT04344782\n\n",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2004, approved to treat certain types of cancer",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/27/2020"
      }
   ],
   "Numerous trials with Chinese research sponsors": [
      {
         "Developer ": {
            " Researcher": "Numerous trials with Chinese research sponsors"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II study not yet recruiting",
         "Product Description": "PD-1 blocking antibody; Thymosin",
         "Clinical Trials for COVID-19": "NCT04268537        \n\nChiCTR2000030028 ",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "Unknown",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/27/2020"
      },
      {
         "Developer ": {
            " Researcher": "Numerous trials with Chinese research sponsors"
         },
         "Treatment vs. Vaccine": "Dormant / Discontinued",
         "Product Category": "Dormant / Discontinued",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Chinese trial site last updated February 16, 2020 - March 4, 2020 for various trials ",
         "Product Description": "azvudine, reverse transcriptase inhibitor\n",
         "Clinical Trials for COVID-19": "ChiCTR2000030487\n\nChiCTR2000030424\n\nChiCTR2000029853",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Centivax (Distributed Bio)": [
      {
         "Developer ": {
            " Researcher": "Centivax (Distributed Bio)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibody",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/21/2020"
      }
   ],
   "Tang-Du Hospital": [
      {
         "Developer ": {
            " Researcher": "Tang-Du Hospital"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II/III recruiting April 2020",
         "Product Description": "meplazumab, anti-CD147 antibody",
         "Clinical Trials for COVID-19": "NCT04275245",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.03.21.20040691)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/27/2020"
      }
   ],
   "Regeneron/ NIAID": [
      {
         "Developer ": {
            " Researcher": "Regeneron/ NIAID"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Joined Operation Warp Speed in July 2020; Phase III prevention trial with NIAID starts July 2020; Phase II stage of I/II/III treatment trial started July 2020",
         "Product Description": "Antibody combination REGN-COV2 (REGN10933+REGN10987) against the spike protein",
         "Clinical Trials for COVID-19": "NCT04425629, NCT04426695, NCT04452318",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "AstraZeneca; ACCORD trial ": [
      {
         "Developer ": {
            " Researcher": "AstraZeneca; ACCORD trial "
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "ACCORD Phase II trial to start May 2020",
         "Product Description": "MEDI3506, monoclonal antibody targeting interleukin 33",
         "Clinical Trials for COVID-19": "",
         "Funder": "UK Government (ACCORD study)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Chronic Obstructive Pulmonary Diesase"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/10/2020"
      }
   ],
   "Ligand Pharmaceuticals": [
      {
         "Developer ": {
            " Researcher": "Ligand Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibodies (OmniChicken platform)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/23/2020"
      },
      {
         "Developer ": {
            " Researcher": "Ligand Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibodies (OmniRat platform)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/23/2020"
      }
   ],
   "Kamada/ Kedrion Biopharma": [
      {
         "Developer ": {
            " Researcher": "Kamada/ Kedrion Biopharma"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Individual Expanded Access use in Israel started in June 2020; Phase I/II in hospitalized patients in Israel to start 3Q 2020; Will talk to FDA in 3Q 2020",
         "Product Description": "Antibodies from recovered COVID-19 patients",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Harbour BioMed / Erasmus MC / Utrecht University / Mount Sinai Health System / AbbVie": [
      {
         "Developer ": {
            " Researcher": "Harbour BioMed / Erasmus MC / Utrecht University / Mount Sinai Health System / AbbVie"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibody 47D11",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/9/2020"
      }
   ],
   "Emergent BioSolutions / National Institute of Allergy and Infectious Diseases (NIAID)": [
      {
         "Developer ": {
            " Researcher": "Emergent BioSolutions / National Institute of Allergy and Infectious Diseases (NIAID)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase II trials begin ~August 2020",
         "Product Description": "Polyclonal hyperimmune globulin (H-IG)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same human hyperimmune platform as FDA-approved anthrax treatment (Anthrasil) and smallpox vaccine complications (VIGIV) were developed"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Eli Lilly / AbCellera (NIH Vaccines Research Center)": [
      {
         "Developer ": {
            " Researcher": "Eli Lilly / AbCellera (NIH Vaccines Research Center)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I started June 2020; results expected end of June 2020",
         "Product Description": "LY-CoV555 antibody from recovered patients",
         "Clinical Trials for COVID-19": "NCT04411628, NCT04427501",
         "Funder": "Defense Advanced Research Projects Agency/ Government of Canada (ISED Strategic Innovation Fund)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Chelsea and Westminster Hospital, Imperial College London": [
      {
         "Developer ": {
            " Researcher": "Chelsea and Westminster Hospital, Imperial College London"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibodies",
         "Clinical Trials for COVID-19": "",
         "Funder": "UK Government",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/10/2020"
      }
   ],
   "GSK": [
      {
         "Developer ": {
            " Researcher": "GSK"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II recruiting June 2020",
         "Product Description": "otilimab, anti-granulocyte macrophase colony-stimulating factor (GM-CSF) antibody\n",
         "Clinical Trials for COVID-19": "NCT04376684",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "To treat rheumatoid arthritis\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/10/2020"
      }
   ],
   "Eli Lilly": [
      {
         "Developer ": {
            " Researcher": "Eli Lilly"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II to start in April 2020",
         "Product Description": "LY3127804, anti-Angiopoietin 2 (Ang2) antibody",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Edesa Biotech / Light Chain Bioscience (NovImmune)": [
      {
         "Developer ": {
            " Researcher": "Edesa Biotech / Light Chain Bioscience (NovImmune)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Monocloncal antibodies, CXC10 antagonist",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/23/2020"
      }
   ],
   "CoVIg-19 Plasma Alliance (Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, Sanquin)/ National Institute of Allergy and Infectious Disease (NIAID)/ Microsoft (CoVIg-19 PlasmaBot)": [
      {
         "Developer ": {
            " Researcher": "CoVIg-19 Plasma Alliance (Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, Sanquin)/ National Institute of Allergy and Infectious Disease (NIAID)/ Microsoft (CoVIg-19 PlasmaBot)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I trials start in summer 2020; To patients between December 2020 and December 2021",
         "Product Description": "Polyclonal hyperimmune globulin (H-IG), unbranded",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/10/2020"
      }
   ],
   "Multiple global research sponsors; Octapharma USA/ Sharp Memorial Hospital": [
      {
         "Developer ": {
            " Researcher": "Multiple global research sponsors; Octapharma USA/ Sharp Memorial Hospital"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Sharpy Memorial Hospital preliminary data released June 2020; Phase III trial to start May 2020",
         "Product Description": "Octagam; intravenous Immunoglobulin (IVIG)",
         "Clinical Trials for COVID-19": "NCT04261426\n\nNCT04264858\n\nNCT04350580",
         "Funder": "Unknown",
         "Published Results": "Open Forum Infectious Diseases (https://academic.oup.com/ofid/article/7/3/ofaa102/5810740), (https://www.businesswire.com/news/home/20200603005130/en/Octapharma-USA-Extends-Funding-COVID-19-Study-Positive), medRxiv (https://doi.org/10.1101/2020.06.15.20132407)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2014, approved to treat chronic immune thrombocytopenic purpura (ITP)",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/22/2020"
      }
   ],
   "Abcore": [
      {
         "Developer ": {
            " Researcher": "Abcore"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Single domain antibodies (sdAbs), engineered monoclonal antibody derived from camelids",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/21/2020"
      }
   ],
   "Celltrion": [
      {
         "Developer ": {
            " Researcher": "Celltrion"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      },
      {
         "Developer ": {
            " Researcher": "Celltrion"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase I in July 2020",
         "Product Description": "CT-P59; Antibodies from recovered COVID-19 patients\n",
         "Clinical Trials for COVID-19": "",
         "Funder": "The Korea Health Industry Development Institute",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/5/2020"
      },
      {
         "Developer ": {
            " Researcher": "Celltrion"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial to start in June 2020",
         "Product Description": "Remsima (infliximab), anti-TNF antibody",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2016, approved to treat various autoimmune diseases",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/12/2020"
      }
   ],
   "Wuhan Jinyintan Hospital": [
      {
         "Developer ": {
            " Researcher": "Wuhan Jinyintan Hospital"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "No trial updates since February 2020\n",
         "Product Description": "AiRuiKa (camrelizumab), anti-programmed cell death protein (PD-1) antibody",
         "Clinical Trials for COVID-19": "ChiCTR2000029806",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treatment of certain cancers"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/27/2020"
      }
   ],
   "University of Texas at Austin / US National Institutes of Health / Ghent University": [
      {
         "Developer ": {
            " Researcher": "University of Texas at Austin / US National Institutes of Health / Ghent University"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Linked nanobody antibody",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/1/2020"
      }
   ],
   "Xbiotech / BioBridge Global": [
      {
         "Developer ": {
            " Researcher": "Xbiotech / BioBridge Global"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibodies from recovered COVID-19 patients",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "FairJourney Biologics / Iontas": [
      {
         "Developer ": {
            " Researcher": "FairJourney Biologics / Iontas"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibodies",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/21/2020"
      }
   ],
   "Assistance Publique - Hopitaux de Paris (Phase II); Alexion (Expanded Access Protocols)": [
      {
         "Developer ": {
            " Researcher": "Assistance Publique - Hopitaux de Paris (Phase II); Alexion (Expanded Access Protocols)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II recruiting May 2020. Expanded access protocols",
         "Product Description": "Soliris (eculizumab), complement inhibitor",
         "Clinical Trials for COVID-19": "NCT04288713\n\nNCT04346797\n\nNCT04355494 ",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2007, approved to treat Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/5/2020"
      }
   ],
   "Alexion Pharmaceuticals. TACTIC-R trial": [
      {
         "Developer ": {
            " Researcher": "Alexion Pharmaceuticals. TACTIC-R trial"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III to start in May 2020",
         "Product Description": "Ultomiris (ravulizumab-cwvz), complement inhibitor",
         "Clinical Trials for COVID-19": "NCT04369469",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2018, aprpoved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/13/2020"
      }
   ],
   "GigaGen": [
      {
         "Developer ": {
            " Researcher": "GigaGen"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), polyclonal antibodies",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N//A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Vir Biotechnology / GSK / Samsung / WuXi Biologics / Biogen": [
      {
         "Developer ": {
            " Researcher": "Vir Biotechnology / GSK / Samsung / WuXi Biologics / Biogen"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase II ~July-September 2020",
         "Product Description": "VIR-7831 and VIR-7832, antibodies from recovered SARS patients",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/20/2020"
      }
   ],
   "Swedish Orphan Biovitrum": [
      {
         "Developer ": {
            " Researcher": "Swedish Orphan Biovitrum"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II/III recruiting April 2020",
         "Product Description": "Gamifant (emapalumab), anti-interferon gamma antibody",
         "Clinical Trials for COVID-19": "NCT04324021",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2018, approved to treat primary hemophagocytic lymphohistiocytosis",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/27/2020"
      }
   ],
   "ImmunoPrecise Antibodies": [
      {
         "Developer ": {
            " Researcher": "ImmunoPrecise Antibodies"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Monoclonal antibody cocktail",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/23/2020"
      }
   ],
   "CytoDyn": [
      {
         "Developer ": {
            " Researcher": "CytoDyn"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial (mild/moderate) met enrollment in June 2020; Phase IIb/III trial (severe) ongoing June 2020, interim results expected June/July 2020",
         "Product Description": "leronlimab (PRO 140), a CCR5 antagonist",
         "Clinical Trials for COVID-19": "NCT04343651      \n\nNCT04347239",
         "Funder": "Unknown",
         "Published Results": "CytoDyn (https://www.cytodyn.com/newsroom/press-releases/detail/415/southern-california-patients-treated-with-leronlimab-for)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancers"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/22/2020"
      }
   ],
   "Grifols": [
      {
         "Developer ": {
            " Researcher": "Grifols"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Polyclonal hyperimmune globulin (H-IG)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      },
      {
         "Developer ": {
            " Researcher": "Grifols"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibodies from recovered COVID-19 patients",
         "Clinical Trials for COVID-19": "",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "EUSA Pharma / The Papa Giovanni XXII Hospital; University Hospital, Ghent; Fundacion Clinic per a la Recerca Biomédica": [
      {
         "Developer ": {
            " Researcher": "EUSA Pharma / The Papa Giovanni XXII Hospital; University Hospital, Ghent; Fundacion Clinic per a la Recerca Biomédica"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "FDA approves Phase III trial in hospitalized patients in July 2020",
         "Product Description": "Sylvant (siltuximab), interleukin-6 targeted monoclonal",
         "Clinical Trials for COVID-19": "NCT04322188\n\nNCT04330638\n\nNCT04329650",
         "Funder": "Unknown",
         "Published Results": "EUSA Pharma (https://www.eusapharma.com/news/interim-analysis-data-for-siltuximab-treated-covid-19-patients-from-the-sisco-study/)       \n\nmedRxiv (https://doi.org/10.1101/2020.04.01.20048561)\n\nmedRxiv (https://doi.org/10.1101/2020.04.23.20076612)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2014, approved to treat multicentric Castleman disease",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/7/2020"
      }
   ],
   "Vanderbilt Vaccine Center / AstraZeneca / IDBiologics": [
      {
         "Developer ": {
            " Researcher": "Vanderbilt Vaccine Center / AstraZeneca / IDBiologics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I trial begins in August 2020",
         "Product Description": "Combo of two antibodies",
         "Clinical Trials for COVID-19": "",
         "Funder": "Defense Advanced Research Projects Agency/ Dolly Parton/ Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/15/2020"
      }
   ],
   "Numerous trials with global research sponsors; Roche; REMAP-CAP; RECOVERY": [
      {
         "Developer ": {
            " Researcher": "Numerous trials with global research sponsors; Roche; REMAP-CAP; RECOVERY"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Initial Roche studies could be completed May or June 2020; Phase II open label study in Italy active (April 2020), Phase III Roche global trial enrolling May 2020, Roche trial (+ remdesivir) to start June 2020",
         "Product Description": "Actemra (tocilizumab), interleukin-6 receptor antagonist",
         "Clinical Trials for COVID-19": "NCT04317092, NCT04320615, NCT04310228, ChiCTR2000030894, NCT04306705, ChiCTR2000030442, ChiCTR2000029765, NCT04322773, NCT04345445, NCT04331795, NCT04332094, NCT04346355, NCT04359667, NCT04332913, NCT04335071, NCT04356937, NCT04361032, NCT04315480, NCT04339712, NCT04333914, NCT04361552, NCT04330638, NCT04331808, NCT02735707, NCT04349410, NCT04363736, NCT04372186, NCT04363853",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "ChinaXiv (http://www.chinaxiv.org/abs/202003.00026), medRxiv (https://doi.org/10.1101/2020.04.20.20061861), medRxiv (https://doi.org/10.1101/2020.04.23.20076612), Assistance Publique Hopitaux De Paris (https://www.aphp.fr/contenu/le-tocilizumab-ameliore-significativement-le-pronostic-des-patients-avec-pneumonie-covid), PNAS (https://www.pnas.org/content/early/2020/04/27/2005615117#T1), medRxiv (https://doi.org/10.1101/2020.05.01.20078360), medRxiv (https://doi.org/10.1101/2020.05.07.20094599), medRxiv (https://doi.org/10.1101/2020.05.14.20099234), medRxiv (https://doi.org/10.1101/2020.05.13.20100404), medRxiv (https://doi.org/10.1101/2020.05.13.20100081), medRxiv (https://doi.org/10.1101/2020.05.21.20109207), medRxiv (https://doi.org/10.1101/2020.06.12.20122374), medRxiv (https://doi.org/10.1101/2020.06.08.20125245), medRxiv (https://doi.org/10.1101/2020.06.06.20122341), medRxiv (https://doi.org/10.1101/2020.06.05.20122622), medRxiv (https://doi.org/10.1101/2020.06.03.20121558), medRxiv (https://doi.org/10.1101/2020.06.05.20113738), medRxiv (https://doi.org/10.1101/2020.06.01.20119149), medRxiv (https://doi.org/10.1101/2020.05.29.20117358), medRxiv (https://doi.org/10.1101/2020.06.13.20130088), Italian Medicines Agency (https://www.aifa.gov.it/web/guest/-/covid-19-studio-randomizzato-italiano-nessun-beneficio-dal-tocilizumab), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), EClinicalMed (https://doi.org/10.1016/j.eclinm.2020.100418), Lancet Rheumatology (https://doi.org/10.1016/S2665-9913(20)30173-9), medRxiv (https://doi.org/10.1101/2020.06.23.20134072), medRxiv (https://doi.org/10.1101/2020.06.22.20133413), medRxiv (https://doi.org/10.1101/2020.06.24.20134288), The Lancet (https://doi.org/10.1016/j.eclinm.2020.100410)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2010, approved to treat various type of arthritis, including rheumatoid arthritis and cytokine release syndrome",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/7/2020"
      }
   ],
   "Tsinghua University / Third People's Hospital of Shenzhen / Brii Biosciences": [
      {
         "Developer ": {
            " Researcher": "Tsinghua University / Third People's Hospital of Shenzhen / Brii Biosciences"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I trial begins Q3 2020",
         "Product Description": "Antibodies from recovered COVID-19 patients",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Sanofi / Regeneron; Feinstein Institutes; REMAP-CAP global trial": [
      {
         "Developer ": {
            " Researcher": "Sanofi / Regeneron; Feinstein Institutes; REMAP-CAP global trial"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III (US) results released July 2020 and US trial stopped, Phase III (ex-US in severe and critical hospitalized patients continues) results expected 3Q 2020",
         "Product Description": "Kevzara (sarilumab), interleukin-6 receptor antagonist",
         "Clinical Trials for COVID-19": "NCT04315298, NCT04321993, NCT04341870, NCT04324073, NCT04327388, NCT04322773, NCT04345289, NCT02735707, NCT04357808, NCT04357860, NCT04359901",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.04.23.20076612)Regeneron (https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive)ChinaXiv (http://www.chinaxiv.org/abs/202003.00026)medRxiv (https://doi.org/10.1101/2020.05.14.20094144), Regeneron (https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-kevzarar-sarilumab-phase-3)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2017, approved to treat rheumatoid\n arthritis",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/7/2020"
      }
   ],
   "Public Health England (Stuart Dowall)": [
      {
         "Developer ": {
            " Researcher": "Public Health England (Stuart Dowall)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Purified ovine immunoglobulin from immunized sheep",
         "Clinical Trials for COVID-19": "",
         "Funder": "UK Government",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/23/2020"
      }
   ],
   "Humanigen Inc.": [
      {
         "Developer ": {
            " Researcher": "Humanigen Inc."
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Data on first clinical use released June 2020; Phase III trial recruiting June 2020",
         "Product Description": "lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody",
         "Clinical Trials for COVID-19": "NCT04351152",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.06.08.20125369), (https://www.humanigen.com/press/Humanigen-Reports-Additional-Analysis-of-Lenzilumab-in-Severe-and-Critical-COVID-19-Patients)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthma"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Novartis; other research sponsors\n": [
      {
         "Developer ": {
            " Researcher": "Novartis; other research sponsors\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Novartis Phase III to start and trial top-line results expected late summer 2020",
         "Product Description": "Ilaris (canakinumab), interleukin-1beta blocker",
         "Clinical Trials for COVID-19": "NCT04348448\n\nNCT04362813\n\nNCT04365153",
         "Funder": "Unknown",
         "Published Results": "The Lancet Rheumatology (https://doi.org/10.1016/S2665-9913(20)30167-3)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2009, approved to treat periodic fever syndromes and systemic juvenile idiopathic arthritis",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/9/2020"
      }
   ],
   "Junshi Biosciences / Eli Lilly": [
      {
         "Developer ": {
            " Researcher": "Junshi Biosciences / Eli Lilly"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I trial in China started June 2020; trial in US to start 2H 2020   ",
         "Product Description": "JS016 antibody candidate\n",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/9/2020"
      }
   ],
   "Medicago / Laval University's Infectious Disease Research Centre": [
      {
         "Developer ": {
            " Researcher": "Medicago / Laval University's Infectious Disease Research Centre"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibodies",
         "Clinical Trials for COVID-19": "",
         "Funder": "Canadian Institutes for Health Research (CIHR)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "I-Mab Biopharma": [
      {
         "Developer ": {
            " Researcher": "I-Mab Biopharma"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Interim Phase I/II data released June 2020, part 2 of the study to start June 2020",
         "Product Description": "TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody",
         "Clinical Trials for COVID-19": "NCT04341116",
         "Funder": "Unknown",
         "Published Results": "PR Newswire (https://www.prnewswire.com/news-releases/i-mab-reports-interim-results-from-part-1-study-for-anti-gm-csf-antibody-tjm2-to-treat-covid-19-patients-with--cytokine-release-syndrome-301066451.html)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/2/2020"
      }
   ],
   "Innovent Biologics": [
      {
         "Developer ": {
            " Researcher": "Innovent Biologics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibodies from recovered COVID-19 patients",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Sorrento Therapeutics / Mount Sinai Health System": [
      {
         "Developer ": {
            " Researcher": "Sorrento Therapeutics / Mount Sinai Health System"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase II trial Q3 2020",
         "Product Description": "COVI-SHIELD antibody cocktail that binds to three different epitopes",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/20/2020"
      }
   ],
   "AstraZeneca / US Army Medical Research Institute of Infectious Diseases (USAMRIID) / University of Maryland School of Medicine": [
      {
         "Developer ": {
            " Researcher": "AstraZeneca / US Army Medical Research Institute of Infectious Diseases (USAMRIID) / University of Maryland School of Medicine"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I trials begin in summer 2020",
         "Product Description": "Antibodies targeting the S protein from convalescent serum, humanized mice, and phage display",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Costa Rican Social Security Fund (CCSS)/ The University of Costa Rica (UCR)/ Clodomiro Picado Institute": [
      {
         "Developer ": {
            " Researcher": "Costa Rican Social Security Fund (CCSS)/ The University of Costa Rica (UCR)/ Clodomiro Picado Institute"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibodies from recovered COVID-19 patients",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Prellis Biologics": [
      {
         "Developer ": {
            " Researcher": "Prellis Biologics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I trial could begin as early as Sept 2020",
         "Product Description": "Antibodies",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Emergent BioSolutions": [
      {
         "Developer ": {
            " Researcher": "Emergent BioSolutions"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase II trials begin ~August 2020",
         "Product Description": "Horse plasma product (COVID-EIG)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same equine hyperimmune platform as FDA-approved botulism anti-toxin (BAT) is produced"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "CSL Behring / SAb Biotherapeutics": [
      {
         "Developer ": {
            " Researcher": "CSL Behring / SAb Biotherapeutics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I starts early summer 2020",
         "Product Description": "SAB-185, Polyclonal hyperimmune globulin (H-IG)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "CSL Behring Australia\n": [
      {
         "Developer ": {
            " Researcher": "CSL Behring Australia\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "COVID-19 Immunoglobulin, plasma derived\n",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/10/2020"
      }
   ],
   "Amgen / Adaptive Biotechnologies": [
      {
         "Developer ": {
            " Researcher": "Amgen / Adaptive Biotechnologies"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antibodies from recovered COVID-19 patients",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "InflaRx N.V.": [
      {
         "Developer ": {
            " Researcher": "InflaRx N.V."
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II topline results reported June 2020",
         "Product Description": "IFX-1, anti-C5a antibody",
         "Clinical Trials for COVID-19": "NCT04333420",
         "Funder": "Unknown",
         "Published Results": "inflaRx (https://www.inflarx.de/Home/Investors/Press-Releases/06-2020-InflaRx-Reports-Encouraging-Topline-Results-from-the-Exploratory-Phase-II-Part-of-the-Adaptive-Randomized-Phase-II-III-Trial-of-IFX-1-in-COVID-19.html)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "To treat various inflammatory conditions including hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangraenosum"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/22/2020"
      }
   ],
   "Multiple global research sponsors, including New York State Department of Health, Johns Hopkins University, the Feinstein Institutes; RECOVERY trial": [
      {
         "Developer ": {
            " Researcher": "Multiple global research sponsors, including New York State Department of Health, Johns Hopkins University, the Feinstein Institutes; RECOVERY trial"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Mayo Clinic and Houston Methodist trial results published June 2020, other trials ongoing",
         "Product Description": "Convalescent plasma (blood plasma from recovered patients)",
         "Clinical Trials for COVID-19": "Many expanded access, observational, patient registry, plasma collection, prevention, and other studies listed in clinicaltrials.gov, including: NCT04321421, NCT04292340, NCT04316728, NCT04338360, NCT04345289, NCT04349410, NCT04346589, NCT04333251, NCT04361253, NCT04323800, NCT04359810, NCT04362176, NCT04354831, NCT04360486, NCT04321421, NCT04441424",
         "Funder": "Bloomberg Philantropies and the State of Maryland (to Johns Hopkins University)/Biomedical Advanced Research and Development Authority (BARDA) (to Mayo Clinic)",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.03.16.20036145), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2763983), medRxiv (https://doi.org/10.1101/2020.04.07.20056440), JAMA Network (https://jamanetwork.com/journals/jama/fullarticle/2763982), medRxiv (https://doi.org/10.1101/2020.05.08.20095471), medRxiv (https://doi.org/10.1101/2020.05.12.20099879), Amer J Pathology (https://ajp.amjpathol.org/article/S0002-9440(20)30257-1/fulltext), medRxiv (https://doi.org/10.1101/2020.05.20.20102236), JAMA (https://jamanetwork.com/journals/jama/article-abstract/2766943), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2766940), (https://ctmirror.org/2020/05/17/cautious-enthusiasm-for-plasma-treatment-in-covid-19-cases/), (https://www.wbtv.com/2020/06/11/novant-health-physicians-say-convalescent-plasma-therapy-is-showing-promising-results-covid-fight/), medRxiv (https://doi.org/10.1101/2020.06.05.20122820), medRxiv (https://doi.org/10.1101/2020.05.26.20113373), medRxiv (https://doi.org/10.1101/2020.05.21.20109512), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), medRxiv (https://doi.org/10.1101/2020.06.19.20135830), medRxiv (https://doi.org/10.1101/2020.06.21.20132944), Mayo Clinic Proceedings (https://mayoclinicproceedings.org/pb/assets/raw/Health%20Advance/journals/jmcp/jmcp_ft95_6_8.pdf), medRxiv (https://doi.org/10.1101/2020.06.24.20121905)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      }
   ],
   "Cerecor": [
      {
         "Developer ": {
            " Researcher": "Cerecor"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase 2 to start in June 2020, top line data expected 4Q 2020",
         "Product Description": "CERC-002, anti-LIGHT monoclonal antibody",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Pediatric Crohn's Disease"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/2/2020"
      }
   ],
   "Tychan/ SingHealth Investigational Medicine Unit": [
      {
         "Developer ": {
            " Researcher": "Tychan/ SingHealth Investigational Medicine Unit"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I started June 2020; efficacy data expected 3Q 2020",
         "Product Description": "TY027, monoclonal antibody targeting SARS-CoV-2",
         "Clinical Trials for COVID-19": "",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "IGY Life Sciences/ MMS Holdings/ Canadian Government National Microbiology Lab": [
      {
         "Developer ": {
            " Researcher": "IGY Life Sciences/ MMS Holdings/ Canadian Government National Microbiology Lab"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "",
         "Product Description": "IgY-110, anti-CoV-2 antibody (nasal spary application)",
         "Clinical Trials for COVID-19": "",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Alliance\n  - Proteona/ NMI/ NUS Enterprise/10X Genomics; NovogeneAIT/ Twist Bioscience/\n  University Hospitals": [
      {
         "Developer ": {
            " Researcher": "Alliance\n  - Proteona/ NMI/ NUS Enterprise/10X Genomics; NovogeneAIT/ Twist Bioscience/\n  University Hospitals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "",
         "Product Description": "Antibody for immunocompromised patients",
         "Clinical Trials for COVID-19": "",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Virna\n  Therapeutics/ University of Toronto": [
      {
         "Developer ": {
            " Researcher": "Virna\n  Therapeutics/ University of Toronto"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "",
         "Product Description": "Neutralizing antibodies",
         "Clinical Trials for COVID-19": "",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Kiniksa/\n  Cleveland Clinic/ Ospedale San Raffaele": [
      {
         "Developer ": {
            " Researcher": "Kiniksa/\n  Cleveland Clinic/ Ospedale San Raffaele"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial recruiting June 2020; Case reports published June 2020",
         "Product Description": "mavrilimumab, anti-granulocyte-macrophase colony-stimunlating factor receptor-alpha monoclonal antibody",
         "Clinical Trials for COVID-19": "NCT04399980, NCT04397497",
         "Funder": "",
         "Published Results": "Lancet (https://doi.org/10.1016/S2665-9913(20)30170-3)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Giant cell arteritis (GCA); rheumatoid arthritis; large B-cell lymphoma (with Yescarta)"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/22/2020"
      }
   ],
   "Staidson/ Pivotal": [
      {
         "Developer ": {
            " Researcher": "Staidson/ Pivotal"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "BDB-100, monocloncal anti-C5a antibody",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/26/2020"
      }
   ],
   "Tiziana Life Sciences": [
      {
         "Developer ": {
            " Researcher": "Tiziana Life Sciences"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Plan to initiate Phase 1 in Q1 2021",
         "Product Description": "TZLS-501, an anti-interleukin-6 receptor monoclonal antibody (inhalation technology in development)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/1/2020"
      }
   ],
   "BioCon/ Equilium ": [
      {
         "Developer ": {
            " Researcher": "BioCon/ Equilium "
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "itolizumab, anti-CD6 IgG1 monoclonal antibody",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Graft versus host disease; Lupus nephritis; Plaque psoriasis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "GC Pharma/ Korea National Institute of Health": [
      {
         "Developer ": {
            " Researcher": "GC Pharma/ Korea National Institute of Health"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase II/III to start in July 2020",
         "Product Description": "GC5131A, plasma derived therapy",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Cologne  University Hospital/ German Center for Infection Research/ Boehringer Ingelheim": [
      {
         "Developer ": {
            " Researcher": "Cologne  University Hospital/ German Center for Infection Research/ Boehringer Ingelheim"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antibodies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Clinical trials to start in 2020",
         "Product Description": "Antibodies from recovered COVID-19 patients",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "SCORE consortium (universities of Aix-Marseille, Leuven, Utrecht, Bern, and Lubeck), the Helmholtz Centre for Infection Research, and Janssen Pharmaceutica NV": [
      {
         "Developer ": {
            " Researcher": "SCORE consortium (universities of Aix-Marseille, Leuven, Utrecht, Bern, and Lubeck), the Helmholtz Centre for Infection Research, and Janssen Pharmaceutica NV"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antiviral drug combinations",
         "Clinical Trials for COVID-19": "",
         "Funder": "EU Commission (Horizon 2020 Program)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "Unknown",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Beech Tree Labs\n": [
      {
         "Developer ": {
            " Researcher": "Beech Tree Labs\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Has been used in 36 patients anecdotally\n",
         "Product Description": "BTL-tml\n",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treatment of herpes virus infections\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/5/2020"
      }
   ],
   "BioCryst Pharmaceuticals": [
      {
         "Developer ": {
            " Researcher": "BioCryst Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase Ib recruiting May 2020",
         "Product Description": "galidesivir",
         "Clinical Trials for COVID-19": "NCT03891420",
         "Funder": "National Institute of Allergy and Infectious Diseases (NIAID)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treatment of yellow fever"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Acer Therapeutics / US National Center for Advancing Translational Sciences (NCATS)": [
      {
         "Developer ": {
            " Researcher": "Acer Therapeutics / US National Center for Advancing Translational Sciences (NCATS)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II/III to start in Q3 2020",
         "Product Description": "emetine hydrochloride\n",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "To treat viral hepatitis and varicella-virus\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/13/2020"
      }
   ],
   "Ansun Biopharma / Renmin Hospital of Wuhan University": [
      {
         "Developer ": {
            " Researcher": "Ansun Biopharma / Renmin Hospital of Wuhan University"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Individual patient expanded access finding released in May 2020; Phase II/III started enrolling in May 2020",
         "Product Description": "DAS181, recombinant sialidase (nebulized)\n",
         "Clinical Trials for COVID-19": "NCT03808922\n\nNCT04354389\n\nNCT04298060\n\nNCT04324489",
         "Funder": "Unknown",
         "Published Results": "PR Newswire (https://www.prnewswire.com/news-releases/ansun-biopharma-announces-positive-results-from-investigator-initiated-trial-of-novel-covid-19-treatment-301033871.html)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treatment of lower respiratory tract parainfluenza virus infections and severe influenza infections"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/5/2020"
      }
   ],
   "Fujifilm Toyama Chemical / Zhejiang Hisun Pharmaceuticals/numerous trials with global research sponsors / Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School / Glenmark Pharmaceuticals": [
      {
         "Developer ": {
            " Researcher": "Fujifilm Toyama Chemical / Zhejiang Hisun Pharmaceuticals/numerous trials with global research sponsors / Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School / Glenmark Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Fuijfilm trial initial results released July 2020; Phase III trial in India started May 2020 with results expected by July/August 2020 (Glenmark)",
         "Product Description": "Favilavir/Favipiravir/T-705/Avigan, licensed in Japan to treat influenza",
         "Clinical Trials for COVID-19": "NCT04303299, NCT04310228, ChiCTR2000029548, ChiCTR2000029496, ChiCTR2000029544, ChiCTR2000030254, NCT04336904, NCT04333589, NCT04345419",
         "Funder": "Life Arc (FLARE trial; PIONEER trial)",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.03.17.20037432), medRxiv (https://doi.org/10.1101/2020.04.21.20066761), Kyodo News (https://english.kyodonews.net/news/2020/05/fce701d4d88d-antiflu-avigan-not-showing-apparent-efficacy-in-coronavirus-treatment.html), Critical Care (https://doi.org/10.1186/s13054-020-03078-z), (https://asia.nikkei.com/Business/Pharmaceuticals/Fujifilm-s-Avigan-inconclusive-as-COVID-19-treatment-in-Japan-trial)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/13/2020"
      }
   ],
   "ViralClear Pharmaceuticals": [
      {
         "Developer ": {
            " Researcher": "ViralClear Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Vicromax, broad spectrum antiviral",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      },
      {
         "Developer ": {
            " Researcher": "ViralClear Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial recruiting July 2020",
         "Product Description": "merimepodib, IMPDH inhibitor",
         "Clinical Trials for COVID-19": "NCT04410354",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Chronic Hepatitis C; Psoriasis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "ISR Immune System Regulation": [
      {
         "Developer ": {
            " Researcher": "ISR Immune System Regulation"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "ISR-50",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      },
      {
         "Developer ": {
            " Researcher": "ISR Immune System Regulation"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Animal study results expected in Q2 2020, Phase I begins Q4 2020",
         "Product Description": "ISR-50",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Bukwang Pharm": [
      {
         "Developer ": {
            " Researcher": "Bukwang Pharm"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial not yet recruiting",
         "Product Description": "Levovir (clevudine)",
         "Clinical Trials for COVID-19": "NCT04347915",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Agastiya Biotech": [
      {
         "Developer ": {
            " Researcher": "Agastiya Biotech"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start in 2020",
         "Product Description": "AB001",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/24/2020"
      }
   ],
   "Cocrystal Pharma": [
      {
         "Developer ": {
            " Researcher": "Cocrystal Pharma"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antiviral compounds",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Ridgeback Biotherapeutics / Drug Innovation Ventures at Emory (DRIVE)/ Merck": [
      {
         "Developer ": {
            " Researcher": "Ridgeback Biotherapeutics / Drug Innovation Ventures at Emory (DRIVE)/ Merck"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial started June 2020",
         "Product Description": "EIDD-2801, oral ribonucleoside analog",
         "Clinical Trials for COVID-19": "NCT04405739, NCT04405570, NCT04392219",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Ascletis / Chinese research sponsors": [
      {
         "Developer ": {
            " Researcher": "Ascletis / Chinese research sponsors"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III trial recruiting May 2020",
         "Product Description": "ASC09, HIV protease inhibitor",
         "Clinical Trials for COVID-19": "NCT04261907\n\nNCT04261270",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treatment of HIV/AIDS"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      },
      {
         "Developer ": {
            " Researcher": "Ascletis / Chinese research sponsors"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Small open label trial completed and results released in March 2020; Larger open label trial recruiting May 2020",
         "Product Description": "Ganovo (danoprevir), hepatitis C virus NS3 protease inhibitor; ritonavir; interferon, approved in China to treat Hepatitis C",
         "Clinical Trials for COVID-19": "NCT04291729\n\nNCT04345276",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.03.22.20034041)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treatment of Hepatitis C\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Roche; REMAP-CAP global trial": [
      {
         "Developer ": {
            " Researcher": "Roche; REMAP-CAP global trial"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "REMAP-CAP trial recruiting May 2020\n",
         "Product Description": "Tamiflu (oseltamivir), neuraminidase inhibitor",
         "Clinical Trials for COVID-19": "NCT04303299\n\nNCT04255017        \n\nNCT04261270\n\nNCT02735707\n\nNCT04338698\n\nNCT04371601",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.03.28.20045955)       \n\nmedRxiv (https://doi.org/10.1101/2020.04.11.20056523)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1999, approved to treat and prevent influenza",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Plan Nacional sobre el Sida\n": [
      {
         "Developer ": {
            " Researcher": "Plan Nacional sobre el Sida\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III trial recruiting May 2020",
         "Product Description": "Truvada (emtricitabine and tenofovir, both HIV-1 nucleoside analog reverse transcriptase inhibitors)",
         "Clinical Trials for COVID-19": "ChiCTR2000029468\n\nNCT04334928",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2004, approved to treat and prevent HIV-1 infection",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Bausch Health": [
      {
         "Developer ": {
            " Researcher": "Bausch Health"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II recruiting May 2020; Individual patient expanded access",
         "Product Description": "Virazole (ribavirin for inhalation solution)",
         "Clinical Trials for COVID-19": "NCT04356677",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1985, approved to treat lower respiratory tract infections due to RSV",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Atea Pharmaceuticals": [
      {
         "Developer ": {
            " Researcher": "Atea Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial to start May 2020",
         "Product Description": "AT-527, oral purine nucleotide prodrug",
         "Clinical Trials for COVID-19": "NCT04396106",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treatment of Hepatitis C infections"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/21/2020"
      }
   ],
   "Cidara Therapeutics": [
      {
         "Developer ": {
            " Researcher": "Cidara Therapeutics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "antiviral Fc conjugates",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Gilead; World Health Organization SOLIDARITY trial; National Institute of Allergy and Infectious Diseases (NIAID)'s Adaptive COVID-19 Treatment Trial; Feinstein Institutes; I-SPY COVID": [
      {
         "Developer ": {
            " Researcher": "Gilead; World Health Organization SOLIDARITY trial; National Institute of Allergy and Infectious Diseases (NIAID)'s Adaptive COVID-19 Treatment Trial; Feinstein Institutes; I-SPY COVID"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Gilead releases additional data Phase III trial on July 10, 2020; Gilead's Phase Ia trial of inhalant version started July 2020; EU grants conditional authorization July 3, 2020; Gilead starting Phase II/III trial in pediatric patients in June 2020; FDA issued an Emergency Use Authorization on May 1, 2020; Expanded access protocols",
         "Product Description": "remdesivir, nucleotide analog",
         "Clinical Trials for COVID-19": "NCT04257656, NCT04252664, NCT04292730, NCT04292899, NCT04280705, EudraCT 2020-000936-23, NCT04315948, NCT04302766, NCT04323761, NCT04349410, NCT04401579",
         "Funder": "Unknown",
         "Published Results": "NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2007016), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2001191), Stat News (https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/), Reuters (https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gilead-disputes-report-that-coronavirus-drug-trial-flopped-idUSKCN225326), Stat (https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/), medRxiv (https://doi.org/10.1101/2020.04.21.20066761), Gilead (https://www.businesswire.com/news/home/20200429005424/en/Gilead-Announces-Results-Phase-3-Trial-Investigational), NIAID (https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19?utm_campaign=+42538088&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=), Lancet (https://doi.org/10.1016/S0140-6736(20)31022-9), medRxiv (https://doi.org/10.1101/2020.05.02.20088559), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=featured_home), Gilead (https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2007016), medRxiv (https://doi.org/10.1101/2020.05.17.20104711), medRxiv (https://doi.org/10.1101/2020.06.03.20121558), medRxiv (https://doi.org/10.1101/2020.05.26.20109595), medRxiv (https://doi.org/10.1101/2020.05.23.20110932), medRxiv (https://doi.org/10.1101/2020.06.15.20131227), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), medRxiv (https://doi.org/10.1101/2020.06.22.20136531), Gilead (https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treatment of Ebola"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Multiple global research sponsors\n": [
      {
         "Developer ": {
            " Researcher": "Multiple global research sponsors\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase IV trials recruiting May 2020",
         "Product Description": "Arbidol (umifenovir), licensed in Russia and China for treatment of respiratory viral infections",
         "Clinical Trials for COVID-19": "NCT04252885\n\nNCT04350684 \n\nNCT04286503\n\nNCT04260594\n\nNCT04273763",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.03.19.20038984)       Chinese Journal of Infectious Diseases (http://rs.yiigle.com/yufabiao/1182592.htm)     medRxiv (https://doi.org/10.1101/2020.03.17.20037432)       medRxiv (https://doi.org/10.1101/2020.03.28.20045955)       medRxiv (https://doi.org/10.1101/2020.04.08.20057539)        medRxiv (https://doi.org/10.1101/2020.04.06.20042580)       medRxiv (https://doi.org/10.1101/2020.04.11.20056523)medRxiv (https://doi.org/10.1101/2020.04.25.20079079), medRxiv (https://doi.org/10.1101/2020.06.09.20076646), medRxiv (https://doi.org/10.1101/2020.05.30.20117598)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/16/2020"
      },
      {
         "Developer ": {
            " Researcher": "Multiple global research sponsors\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III trials recruiting May 2020",
         "Product Description": "Prezcobix (darunavir, HIV-1 protease inhibitor/cobicistat, CYP3A inhibitor)",
         "Clinical Trials for COVID-19": "ChiCTR2000029541 \n\nNCT04252274\n\nNCT04303299\n\nNCT04304053",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2015, approved to treat HIV-1 infection",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/20/2020"
      },
      {
         "Developer ": {
            " Researcher": "Multiple global research sponsors\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II, Phase II/III, and Phase IV trials recruiting in May 2020",
         "Product Description": "Cozaar (losartan), angiotensin II receptor blocker (ARB)\n",
         "Clinical Trials for COVID-19": "NCT04312009, NCT04311177, NCT04349410, NCT04335123, NCT04343001, NCT04328012, NCT04340557, NCT04447235, NCT04428268",
         "Funder": "COVID-19 Treatment Accelerator \n",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1995, approved to treat hypertension and diabetic nephropathy",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      },
      {
         "Developer ": {
            " Researcher": "Multiple global research sponsors\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase IV trials recruiting May 2020",
         "Product Description": "Diovan (valsartan), angiotensin II receptor blocker (ARB)",
         "Clinical Trials for COVID-19": "NCT04335786\n\nNCT04330300",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1996, approved to treat hypertension, treat heart failure, and reduce cardiovascular mortality in patients after myocardial infarction",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/8/2020"
      },
      {
         "Developer ": {
            " Researcher": "Multiple global research sponsors\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "heparin; low molecular weight heparin (enoxaparin), anticoagulant\n",
         "Clinical Trials for COVID-19": "NCT04366960, NCT04360824, NCT04359277, NCT04354155, NCT04367831, NCT04345848, NCT04373707, NCT04372589, NCT04362085, NCT04344756, NCT04408235, NCT04406389, NCT04400799, NCT04377997, NCT04393805, NCT04427098",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.03.28.20046144), medRxiv (https://doi.org/10.1101/2020.04.15.20067017), medRxiv (https://doi.org/10.1101/2020.04.23.20076851), JACC (http://www.onlinejacc.org/content/early/2020/05/05/j.jacc.2020.05.001?_ga=2.52741547.2046438614.1588863110-2104341714.1587686709), medRxiv (https://doi.org/10.1101/2020.05.27.20114694), J. Thrombosis and Thrombolysis (doi: 10.1007/s11239-020-02162-z), medRxiv (https://doi.org/10.1101/2020.06.22.20134957)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since at least 1993, approved to prevent blood clots and prevent/treat venous thromboembolism and myocardial infarction",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trial": [
      {
         "Developer ": {
            " Researcher": "Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trial"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "WHO discontinues lopinavir-ritonavir arm in the SOLIDARITY trial July 2020; RECOVERY trial results released June 2020 and stopped that trial arm",
         "Product Description": "Kaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitor",
         "Clinical Trials for COVID-19": "NCT04303299\n\nNCT04255017\n\nChiCTR2000029548\n\nChiCTR2000029539\n\nEudraCT 2020-000936-23\n\nNCT04307693\n\nNCT04315948\n\nNCT04252885\n\nNCT04276688\n\nNCT02735707\n\nNCT04321993\n\n2020-001113-21\n\nNCT04286503\n\nNCT04328012\n\nNCT04346147",
         "Funder": "UK Government (University of Oxford RECOVERY trial); Life Arc (FLARE trial)",
         "Published Results": "NEJM (https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true)medRxiv (https://doi.org/10.1101/2020.03.19.20038984)Chinese Journal of Infectious Diseases (http://rs.yiigle.com/yufabiao/1182592.htm)medRxiv (https://doi.org/10.1101/2020.03.28.20045955)medRxiv (https://doi.org/10.1101/2020.04.08.20057539)medRxiv (https://doi.org/10.1101/2020.04.21.20066761)medRxiv (https://doi.org/10.1101/2020.04.25.20079079)medRxiv (https://doi.org/10.1101/2020.04.24.20077735)The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext) medRxiv (https://doi.org/10.1101/2020.05.13.20094193), medRxiv (https://doi.org/10.1101/2020.05.18.20105650), medRxiv (https://doi.org/10.1101/2020.06.05.20123299), medRxiv (https://doi.org/10.1101/2020.05.27.20114470), medRxiv (https://doi.org/10.1101/2020.06.16.20133298), Recovery Trial press release (https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery), WHO (https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2000, approved to treat HIV-1 infection",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/7/2020"
      }
   ],
   "Stanford\n  University/ US Department of Energy's Lawrence Berkeley National Laboratory": [
      {
         "Developer ": {
            " Researcher": "Stanford\n  University/ US Department of Energy's Lawrence Berkeley National Laboratory"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Prophylactic antiviral CRISPR in human cells (PAC-MAN)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/9/2020"
      }
   ],
   "Anivive\n  Lifesciences": [
      {
         "Developer ": {
            " Researcher": "Anivive\n  Lifesciences"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Antivirals",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "",
         "Product Description": "GC376, protease inhibitor",
         "Clinical Trials for COVID-19": "",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Lattice Biologics": [
      {
         "Developer ": {
            " Researcher": "Lattice Biologics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I enrolling April 2020",
         "Product Description": "AmnioBoost, concentrated allogeneic MSCs and cytokines derived from amniotic fluid",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/23/2020"
      }
   ],
   "Naturecell": [
      {
         "Developer ": {
            " Researcher": "Naturecell"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I/IIa trial approved by South Korea Ministry of Food and Drug Safety in March 2020",
         "Product Description": "Astrostem-V, Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "ImmunityBio / NantKwest / Be The Match BioTherapies": [
      {
         "Developer ": {
            " Researcher": "ImmunityBio / NantKwest / Be The Match BioTherapies"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase Ib trial to start June 2020",
         "Product Description": "Bone marrow-derived allogenic mesenchymal stem cells (BM-Allo-MSC)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Numerous trials with global research sponsors": [
      {
         "Developer ": {
            " Researcher": "Numerous trials with global research sponsors"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I trials ongoing May 2020; Phase I/II trials recruiting May 2020; Phase II/III trial recruiting May 2020",
         "Product Description": "Mesenchymal stem cells",
         "Clinical Trials for COVID-19": "30 trials listed in clinicaltrials.gov\n\nChiCTR2000029990\n\nNCT04315987\n\nNCT04302519\n\nNCT04288102\n\nNCT04313322\n\nNCT04273646\n\nNCT04371601\n\nNCT04315987\n\nNCT04252118\n\nNCT04336254\n\nNCT04339660\n\nNCT04371601\n\nNCT04366063",
         "Funder": "Unknown",
         "Published Results": "Aging and Disease (http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml)       \n\nChinaXiv (http://chinaxiv.org/abs/202002.00084)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/8/2020"
      }
   ],
   "Hope Biosciences": [
      {
         "Developer ": {
            " Researcher": "Hope Biosciences"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II started in April 2020",
         "Product Description": "Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)",
         "Clinical Trials for COVID-19": "NCT04348435\n\nNCT04349631\n\nNCT04362189",
         "Funder": "Hope Biosciences Stem Cell Research Foundation",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Rheumatoid arthritis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/24/2020"
      }
   ],
   "ImmunityBio / NantKwest": [
      {
         "Developer ": {
            " Researcher": "ImmunityBio / NantKwest"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Pre-IND submitted to FDA in May 2020",
         "Product Description": "haNK, natural killer cells",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      },
      {
         "Developer ": {
            " Researcher": "ImmunityBio / NantKwest"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase Ib trial to start June 2020",
         "Product Description": "N-803, IL-15 \"superagonist\" (Nogapendekin alfa inbakicept)",
         "Clinical Trials for COVID-19": "NCT04385849",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Bladder Carcinoma In Situ"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Mesoblast/ Cardiothoracic Surgical Trials Network": [
      {
         "Developer ": {
            " Researcher": "Mesoblast/ Cardiothoracic Surgical Trials Network"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Individual patient expanded access; Expanded access protocols; Individual patient expanded access data shared April 2020; Phase III trial recruiting May 2020",
         "Product Description": "Ryoncil (remestemcel-L), allogenic mesenchymal stem cells",
         "Clinical Trials for COVID-19": "NCT04366830\n\nNCT04371393",
         "Funder": "Unknown",
         "Published Results": "Mesoblast (http://investorsmedia.mesoblast.com/static-files/337e723a-340d-493e-a4a1-0971d2c71460)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Graft versus host disease and other rare diseases, chronic obstructive pulmonary disease"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Athersys / The University of Texas Health Science Center at Houston": [
      {
         "Developer ": {
            " Researcher": "Athersys / The University of Texas Health Science Center at Houston"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II/III trial recruiting May 2020",
         "Product Description": "MultiStem, bone marrow stem cells",
         "Clinical Trials for COVID-19": "NCT04367077",
         "Funder": "Medical Technology Enterprise Consortium (MTEC)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Acute Respiratory Distress Syndrome; Stroke"
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/10/2020"
      }
   ],
   "AlloVir / Baylor College of Medicine": [
      {
         "Developer ": {
            " Researcher": "AlloVir / Baylor College of Medicine"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Allogeneic T-cell therapies",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Celltex": [
      {
         "Developer ": {
            " Researcher": "Celltex"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "FDA approves Phase II trial on June 26, 2020",
         "Product Description": "Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)",
         "Clinical Trials for COVID-19": "NCT04428801",
         "Funder": "Unknown",
         "Published Results": "Celltex (https://celltexbank.com/transplantation-of-ace2-mesenchymal-stem-cells-improves-the-outcome-of-patients-with-covid-19-pneumonia/)\n\nCelltex (https://celltexbank.com/chinaxiv-reports-clinical-remission-of-a-critically-ill-covid-19-patient-treated-by-human-umbilical-cord-mesenchymal-stem-cells/)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Injuries, Pain, and Autoimmune, Vascular and Other Disease, including Inflammatory lung conditions, pneumonia, and chronic obstructive pulmonary disease (COPD)"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      }
   ],
   "Celularity/ Lung Biotechnology PBC": [
      {
         "Developer ": {
            " Researcher": "Celularity/ Lung Biotechnology PBC"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I/II study not yet recruiting May 2020",
         "Product Description": "CYNK-001, allogeneic, natural killer cell therapy",
         "Clinical Trials for COVID-19": "NCT04365101",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Various hematologic cancers and solid tumors"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Capricor Inc.": [
      {
         "Developer ": {
            " Researcher": "Capricor Inc."
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Expanded access protocol trial ongoing May 2020",
         "Product Description": "CAP-1002, allogenic cardiosphere-derived cells",
         "Clinical Trials for COVID-19": "NCT04338347",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Duchenne muscular dystrophy"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Pluristem Therapeutics/BIH Center for Regenerative Therapy / Berlin Center for Advanced Therapies": [
      {
         "Developer ": {
            " Researcher": "Pluristem Therapeutics/BIH Center for Regenerative Therapy / Berlin Center for Advanced Therapies"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Results from individual patient expanded access released in April 2020",
         "Product Description": "PLX cell product, placenta-based cell therapy",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "Pluristem Therapeutics (https://www.pluristem.com/wp-content/uploads/2020/04/PSTI-PR-Follow-up-on-Covid-19-treatments-FINAL-FOR-RELEASE.pdf)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Various conditions\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/8/2020"
      }
   ],
   "Duke-NUS Medical School": [
      {
         "Developer ": {
            " Researcher": "Duke-NUS Medical School"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Chimeric antigen receptors (CAR)/T cell receptors (TCR)-T cell therapy ",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/30/2020"
      }
   ],
   "GC LabCell / KLEO Pharmaceuticals": [
      {
         "Developer ": {
            " Researcher": "GC LabCell / KLEO Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Begin Phase I by end of 2020",
         "Product Description": "Natural killer cell-based therapy",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "SMSbiotech": [
      {
         "Developer ": {
            " Researcher": "SMSbiotech"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Small mobile stem (SMS) cells",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/9/2020"
      }
   ],
   "AgeX\n  Therapeutics/ ImStem Biotechnology": [
      {
         "Developer ": {
            " Researcher": "AgeX\n  Therapeutics/ ImStem Biotechnology"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Cell-based therapies",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "",
         "Product Description": "IMS001, human embryonic stem cell-derived mesenchymal stem cells (hES-MSC)",
         "Clinical Trials for COVID-19": "",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Sirnaomics": [
      {
         "Developer ": {
            " Researcher": "Sirnaomics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "RNA-based treatments",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RNAi - testing 150 RNAis",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Vir Biotech / Alnylam Pharmaceuticals": [
      {
         "Developer ": {
            " Researcher": "Vir Biotech / Alnylam Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "RNA-based treatments",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start by the end of 2020",
         "Product Description": "VIR-2703 (ALN-COV) siRNA candidate",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/5/2020"
      }
   ],
   "Mateon Therapeutics": [
      {
         "Developer ": {
            " Researcher": "Mateon Therapeutics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "RNA-based treatments",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II study IND submitted to FDA on April 27, 2020",
         "Product Description": "OT-101, a TGF-Beta antisense drug candidate",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Various cancers"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Neurimmune / Ethris": [
      {
         "Developer ": {
            " Researcher": "Neurimmune / Ethris"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "RNA-based treatments",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start Q4 2020",
         "Product Description": "Inhaled mRNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Sarepta Therapeutics / US Army Medical Research Institute of Infectious Diseases (USAMRIID)": [
      {
         "Developer ": {
            " Researcher": "Sarepta Therapeutics / US Army Medical Research Institute of Infectious Diseases (USAMRIID)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "RNA-based treatments",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Antisense oligonucleotides, peptide conjugated",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/1/2020"
      }
   ],
   "AIM ImmunoTech / National Institute of Infectious Diseases in Japan": [
      {
         "Developer ": {
            " Researcher": "AIM ImmunoTech / National Institute of Infectious Diseases in Japan"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "RNA-based treatments",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Ampligen; (rintatolimod)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "COVID-19 Therapeutics Accelerator": [
      {
         "Developer ": {
            " Researcher": "COVID-19 Therapeutics Accelerator"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Scanning compound libraries",
         "Clinical Trials for COVID-19": "",
         "Funder": "Gates Foundation / Wellcome / Mastercard Impact Fund",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "N/A"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/1/2020"
      }
   ],
   "Vir Biotechnology / GSK": [
      {
         "Developer ": {
            " Researcher": "Vir Biotechnology / GSK"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Identify anti-coronavirus compounds that target cellular host genes",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/29/2020"
      },
      {
         "Developer ": {
            " Researcher": "Vir Biotechnology / GSK"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Unknown",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Southwest Research Institute": [
      {
         "Developer ": {
            " Researcher": "Southwest Research Institute"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Screening drug compounds",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "N/A"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Janssen Pharmaceutical Companies": [
      {
         "Developer ": {
            " Researcher": "Janssen Pharmaceutical Companies"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Scanning library of antiviral compounds",
         "Clinical Trials for COVID-19": "",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "N/A"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Anixa Biosciences / OntoChem": [
      {
         "Developer ": {
            " Researcher": "Anixa Biosciences / OntoChem"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Screening for antiviral drug candidates",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/21/2020"
      }
   ],
   "Vanda Pharmaceuticals / University of Illinois at Chicago": [
      {
         "Developer ": {
            " Researcher": "Vanda Pharmaceuticals / University of Illinois at Chicago"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Screening of drug compounds",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/29/2020"
      }
   ],
   "Queens University Belfast": [
      {
         "Developer ": {
            " Researcher": "Queens University Belfast"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Scanning compounds to repurpose",
         "Clinical Trials for COVID-19": "",
         "Funder": "UK Government",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "N/A"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Healx": [
      {
         "Developer ": {
            " Researcher": "Healx"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Combinations will be ready for pre-clinical testing in May 2020",
         "Product Description": "Artificial intellegence-based screening to identify repurposed drug combinations",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "N/A"
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Materia Medica / Cyclica": [
      {
         "Developer ": {
            " Researcher": "Materia Medica / Cyclica"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Repurposing antiviral drug candidates",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "N/A"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Takeda": [
      {
         "Developer ": {
            " Researcher": "Takeda"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Scanning compounds to repurpose",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "N/A"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Enanta Pharmaceuticals": [
      {
         "Developer ": {
            " Researcher": "Enanta Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Screening new drugs + library of antiviral compounds",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "N/A"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Shionogi / Hokkaido University Research Center for Zoonosis Control": [
      {
         "Developer ": {
            " Researcher": "Shionogi / Hokkaido University Research Center for Zoonosis Control"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Identify novel drugs",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/29/2020"
      }
   ],
   "Nuritas": [
      {
         "Developer ": {
            " Researcher": "Nuritas"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "AI-based screening to identify a peptide cocktail",
         "Clinical Trials for COVID-19": "",
         "Funder": "Partnership for Advanced Computing in Europe (PACE)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/24/2020"
      }
   ],
   "Pfizer": [
      {
         "Developer ": {
            " Researcher": "Pfizer"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Lead candidate (protease inhibitor) to start Phase I trial in Q3 2020",
         "Product Description": "Scanning antiviral compounds previously in development",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "N/A"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Novartis": [
      {
         "Developer ": {
            " Researcher": "Novartis"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Scanning compounds to repurpose",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "N/A"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA": [
      {
         "Developer ": {
            " Researcher": "Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Identified 30 known drugs that inhibit SARS-CoV-2 replication",
         "Product Description": "Identifying drugs to repurpose",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "bioRxiv (https://doi.org/10.1101/2020.04.16.044016)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/21/2020"
      }
   ],
   "The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies": [
      {
         "Developer ": {
            " Researcher": "The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Identifying drugs to repurpose",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Merck": [
      {
         "Developer ": {
            " Researcher": "Merck"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Scanning compounds to repurpose",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "N/A"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Southwest\n  Research Institute/ US Department of Defense (DOD)": [
      {
         "Developer ": {
            " Researcher": "Southwest\n  Research Institute/ US Department of Defense (DOD)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Screening drug compounds",
         "Clinical Trials for COVID-19": "",
         "Funder": "The Henry M. Jackson Foundation for the Advancement of Military Medicine",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Wyss\n  Institute": [
      {
         "Developer ": {
            " Researcher": "Wyss\n  Institute"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Identify FDA-approved drugs to repurpose to prevent or treat COVID-19",
         "Clinical Trials for COVID-19": "",
         "Funder": "US Defense Advanced Research Projects Agency (DARPA)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Exscalate4Cov,\n  public-private consortium": [
      {
         "Developer ": {
            " Researcher": "Exscalate4Cov,\n  public-private consortium"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Screening a chemical library of 500 billion molecules",
         "Clinical Trials for COVID-19": "",
         "Funder": "European Commision's Horizon 2020",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/22/2020"
      }
   ],
   "Quantitative Biosciences Institute Coronavirus Research Group": [
      {
         "Developer ": {
            " Researcher": "Quantitative Biosciences Institute Coronavirus Research Group"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Scanning compounds to repurpose",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Reviewing existing drugs and compounds through mapping viral-human protein interactions",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/1/2020"
      }
   ],
   "Bioxytran": [
      {
         "Developer ": {
            " Researcher": "Bioxytran"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "BXT-25; glycoprotein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Evelo Biosciences/ Rutgers University/ Robert Wood Johnson University Hospital/ TACTIC-E trial (Cambridge University Hospitals NHS Foundation Trust)": [
      {
         "Developer ": {
            " Researcher": "Evelo Biosciences/ Rutgers University/ Robert Wood Johnson University Hospital/ TACTIC-E trial (Cambridge University Hospitals NHS Foundation Trust)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Part of Phase II/III Phase TACTIC-E trial and interim data expected 4Q 2020; Phase II US trial to start July 2020",
         "Product Description": "EDP1815, oral single strain of microbe ",
         "Clinical Trials for COVID-19": "NCT04393246",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Psoriasis and Atopic Dermatitis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/13/2020"
      }
   ],
   "MedinCell/ University of Utah/ Surgisphere Corp; University of Baghdad; Tanta University; other global research sponsors": [
      {
         "Developer ": {
            " Researcher": "MedinCell/ University of Utah/ Surgisphere Corp; University of Baghdad; Tanta University; other global research sponsors"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "ivermectin",
         "Clinical Trials for COVID-19": "NCT04343092, NCT04345419, NCT04351347, NCT04407507, NCT04392713, NCT04425707, NCT04438850, NCT04405843, NCT04429711, NCT04374279, NCT04360356, NCT04381884, NCT04447235",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.06.06.20124461)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1996, approved to treat intestinal parasites and head lice infestations",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Vanda Pharmaceuticals / Feinstein Institutes for Medical Research at Northwell Health": [
      {
         "Developer ": {
            " Researcher": "Vanda Pharmaceuticals / Feinstein Institutes for Medical Research at Northwell Health"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III trial started in April 2020",
         "Product Description": "tradipitant, a neurokinin-1 receptor antagonist",
         "Clinical Trials for COVID-19": "NCT04326426",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Gastroparesis, motion sickness, and atopic dermatitis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/29/2020"
      }
   ],
   "Can-Fite BioPharma": [
      {
         "Developer ": {
            " Researcher": "Can-Fite BioPharma"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "IND (investigational new drug application) expected to be filed with FDA by end of June 2020",
         "Product Description": "piclidenoson, A3 adenosine receptor agonist",
         "Clinical Trials for COVID-19": "NCT04333472",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Rheumatoid arthritis; psoriasis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Eagle Pharmaceuticals / Amneal Pharmaceuticals / Alcami Corporation / Hackensack University Medical Center": [
      {
         "Developer ": {
            " Researcher": "Eagle Pharmaceuticals / Amneal Pharmaceuticals / Alcami Corporation / Hackensack University Medical Center"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Ryanodex (dantrolene sodium), skeletal muscle relaxant",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2014, approved to prevent and treat malignant hyperthermia",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/21/2020"
      }
   ],
   "Novartis / Incyte, numerous researchers globally": [
      {
         "Developer ": {
            " Researcher": "Novartis / Incyte, numerous researchers globally"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Novartis/Incyte Phase III trial started April 2020; Expanded access protocols",
         "Product Description": "Jakafi/jakavi (ruxolitinib)",
         "Clinical Trials for COVID-19": "ChiCTR2000029580, NCT04334044, NCT04331665, NCT04337359, NCT04348071, NCT04338958, NCT04348695, NCT04355793, NCT04354714, NCT04377620, NCT04362137, NCT04366232, NCT04361903, NCT04374149, NCT04338958, NCT04359290, NCT04414098, NCT04403243",
         "Funder": "LIfeArc (RAVEN trial)",
         "Published Results": "J. Allergy & Clinical Immuno. (https://www.jacionline.org/article/S0091-6749(20)30738-7/abstract)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2011, approved to treat myelofibrosis, polycythemia vera, and acute graft-versus-host disease",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/25/2020"
      }
   ],
   "Romark Laboratories; various researchers globally": [
      {
         "Developer ": {
            " Researcher": "Romark Laboratories; various researchers globally"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "nitazoxanide, antiprotozoal",
         "Clinical Trials for COVID-19": "NCT04351347\n\nNCT04348409\n\nNCT04343248\n\nNCT04341493\n\nNCT04345419",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2002, approved to treat diarrhea caused by Giardia lamblia or Cryptosporidum parvum",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/23/2020"
      }
   ],
   "CEL-SCI / University of Georgia Center for Vaccines and Immunology": [
      {
         "Developer ": {
            " Researcher": "CEL-SCI / University of Georgia Center for Vaccines and Immunology"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Peptides targeting the NP protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "Unknown",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Zydus Cadila Group; The Camelot Foundation\n": [
      {
         "Developer ": {
            " Researcher": "Zydus Cadila Group; The Camelot Foundation\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II/III enrolling May 2020",
         "Product Description": "interferon/peginterferon alpha-2b, PegIntron, Sylatron, IntronA, PegiHep \n",
         "Clinical Trials for COVID-19": "NCT04273763\n\nNCT04349410",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.05.29.20109199)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "PegIntron - FDA-approved since 2001, approved to treat hepatitis C; Sylatron - FDA-approved since 2001, approved for the adjuvant treatment of melanoma; Intron A - FDA-approved since 1986, approved to treat hepatitis C and certain cancers",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/16/2020"
      }
   ],
   "Cyclacel Pharmaceuticals / University of Edinburgh": [
      {
         "Developer ": {
            " Researcher": "Cyclacel Pharmaceuticals / University of Edinburgh"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "roscovitine seliciclib, cyclin-dependent kinase (CDK)2/9 inhibitor",
         "Clinical Trials for COVID-19": "",
         "Funder": "LifeArc",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Rheumatoid arthritis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/23/2020"
      },
      {
         "Developer ": {
            " Researcher": "Cyclacel Pharmaceuticals / University of Edinburgh"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "fadraciclib (CYC065), cyclin-dependent kinase (CDK)2/9 inhibitor",
         "Clinical Trials for COVID-19": "",
         "Funder": "LifeArc",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Various cancers"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/23/2020"
      }
   ],
   "aTyr": [
      {
         "Developer ": {
            " Researcher": "aTyr"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II study started in June 2020",
         "Product Description": "ATYR1923, fusion protein (immuno-modulatory domain of histidyl tRNA synthetase fused to the Fc region of a human antibody) modulator of neuropilin-2",
         "Clinical Trials for COVID-19": "NCT04412668",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Pulmonary sarcoidosis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Partner Therapeutics/ Singapore General Hospital/ University Hospital, Ghent": [
      {
         "Developer ": {
            " Researcher": "Partner Therapeutics/ Singapore General Hospital/ University Hospital, Ghent"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II and Phase IV trials recruiting July 2020",
         "Product Description": "Leukine (sargramostim, rhu-Granulocyte macrophage colony stimulating factor )",
         "Clinical Trials for COVID-19": "NCT04326920, NCT04400929, NCT04411680",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Pulmonary conditions that affect alveolar macrophases (nebulized leukine); ARDS (IV leukine)"
         },
         "FDA-Approved Indications": "FDA-approved since 1991, approved to shorten the time to neutrophil recovery and reduce the incidence of infections following chemotherapy, mobilize hematopoietic progenitor cells, accelerate myeloid reconstitution following bone marrow or cell transplantation, treat delayed neutrophil recovery or graft failure after bone marrow transplantation, and increase survival of radiation",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Aldeyra Therapeutics": [
      {
         "Developer ": {
            " Researcher": "Aldeyra Therapeutics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "IND submission to FDA in Q3 2020",
         "Product Description": "ADX-1612, HSP 90 inhibitor",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Various cancers"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/21/2020"
      },
      {
         "Developer ": {
            " Researcher": "Aldeyra Therapeutics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "IND submission to FDA in June 2020",
         "Product Description": "ADX-629, orally available reactive aldehyde species (RASP) inhibitor",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Systemic immune-mediated diseases"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/21/2020"
      }
   ],
   "Chimerix\n": [
      {
         "Developer ": {
            " Researcher": "Chimerix\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II/III trial recruiting July 2020",
         "Product Description": "DSTAT (dociparstat sodium), glycosaminoglycan derivative of heparin\n",
         "Clinical Trials for COVID-19": "NCT04389840",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Acute myeloid leukemia\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Biomarck Pharmaceuticals": [
      {
         "Developer ": {
            " Researcher": "Biomarck Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "BIO-11006, inhaled peptide",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Acute Respiratory Distress Syndrome; Non-Small Cell Lung Cancer; Chronic Obstructive Pulmonary Disease (COPD)"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/24/2020"
      }
   ],
   "Shanghai Jiao Tong University School of Medicine": [
      {
         "Developer ": {
            " Researcher": "Shanghai Jiao Tong University School of Medicine"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III trial recruiting May 2020",
         "Product Description": "Recombinant human interferon alpha-1b",
         "Clinical Trials for COVID-19": "NCT04320238",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.04.11.20061473)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "SciTech Development, LLC": [
      {
         "Developer ": {
            " Researcher": "SciTech Development, LLC"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "ST-001 nanoFenretinide (fenretinide)\n",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "non-Hodgkin's lymphoma"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Beth Israel Deaconess, the University of Colorado Anschultz Medical Campus, and Denver Health (Genentech); University College London": [
      {
         "Developer ": {
            " Researcher": "Beth Israel Deaconess, the University of Colorado Anschultz Medical Campus, and Denver Health (Genentech); University College London"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial recruiting; Individual patient expanded access",
         "Product Description": "Activase (alteplase), tissue plasminogen activator (tPA)",
         "Clinical Trials for COVID-19": "NCT04357730, NCT04356833",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1987, approved to treat stroke, myocardial infarction, and pulmonary embolism",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Multiple global research sponsors, including UK SPIKE-1 trial": [
      {
         "Developer ": {
            " Researcher": "Multiple global research sponsors, including UK SPIKE-1 trial"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I/II, Phase II, and Phase III trials recruiting in May 2020",
         "Product Description": "camostat mesylate, transmembrane protease serine 2 (TMPRSS2) inhibitor, approved in Japan to treat multiple conditions including pancreatitis",
         "Clinical Trials for COVID-19": "NCT04321096, NCT04353284, NCT04338906, NCT04374019, NCT04355052, EudraCT 2020-002233-15",
         "Funder": "LIfeArc (SPIKE-1 trial)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Massachusetts General Hospital; University of British Columbia; Sanotize Research and Development; Bellerophon Pulse Technologies": [
      {
         "Developer ": {
            " Researcher": "Massachusetts General Hospital; University of British Columbia; Sanotize Research and Development; Bellerophon Pulse Technologies"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Mass. General Hopsital Phase II trial ongoing July 2020; other Phase II trials recruiting July 2020",
         "Product Description": "Nitric oxide",
         "Clinical Trials for COVID-19": "NCT04305457, NCT04312243, NCT04306393, NCT03331445, NCT04443868, NCT04337918, NCT04456088, NCT04421508, NCT04383002, NCT04388683, NCT04338828",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1999, approved to improve oxygenation in neonates",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Amgen; I-SPY COVID trial": [
      {
         "Developer ": {
            " Researcher": "Amgen; I-SPY COVID trial"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Otezla (apremilast), inhibitor of phosphodiesterase 4 (PDE4)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2014, approved to treat psoriatic arthritis, severe plaque psoriasis, and oral ulcers associated with Behcet's Disease",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Immunic, Inc.": [
      {
         "Developer ": {
            " Researcher": "Immunic, Inc."
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial started June 2020, top line results expected in 2020",
         "Product Description": "IMU-838, selective oral dihydroorotate dehydrogenase (DHODH) inhibitor",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Ulcerative colitis; remitting multiple sclerosis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Numerous research sponsors globally": [
      {
         "Developer ": {
            " Researcher": "Numerous research sponsors globally"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Open label Greek study results published June 2020",
         "Product Description": "colchicine",
         "Clinical Trials for COVID-19": "NCT04326790, NCT04328480, NCT04322565, NCT04322682, NCT04392141, NCT04375202, NCT04355143, NCT04360980, NCT04350320, NCT04416334, NCT04403243, NCT04363437, NCT04324463, NCT04367168",
         "Funder": "Unknown",
         "Published Results": "JAMA Network Open (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767593)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A (but has been used in the US since the early 1800s, and FDA-approved in combination with probenecid, approved to treat gout)",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/25/2020"
      },
      {
         "Developer ": {
            " Researcher": "Numerous research sponsors globally"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II recruiting July 2020; Individual patient expanded access ",
         "Product Description": "dipyridamole (Persantine), anticoagulant",
         "Clinical Trials for COVID-19": "NCT04424901, NCT04391179, NCT04410328",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.02.27.20027557), Acta Pharm Sin B (https://doi.org/10.1016/j.apsb.2020.04.008)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1961, approved to prevent postoperative thromboembolic complications of cardiac valve replacement",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Innovation Pharmaceuticals": [
      {
         "Developer ": {
            " Researcher": "Innovation Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Brilacidin, a defensin mimetic",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Oral Mucositis; Ulcerative Proctitis/Ulcerative Proctosigmoiditis; Acute Bacterial Skin and Skin Structure Infection"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      }
   ],
   "Arch Biopartners": [
      {
         "Developer ": {
            " Researcher": "Arch Biopartners"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "FDA and Health Canada approved Phase II trial start in June 2020",
         "Product Description": "Metablok (LSALT peptide), selective dipeptidase-1 antagonist",
         "Clinical Trials for COVID-19": "NCT04402957",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Lung and Kidney Inflammation"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Multiple global research sponsors, including University of Tokyo/ National Center for Global Health and Medicine/ Ensysce Biosciences/ Institut Pasteur Korea/ Daiichi Sankyo (inhalation formulation)": [
      {
         "Developer ": {
            " Researcher": "Multiple global research sponsors, including University of Tokyo/ National Center for Global Health and Medicine/ Ensysce Biosciences/ Institut Pasteur Korea/ Daiichi Sankyo (inhalation formulation)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "University of Tokyo trial (IV formulation) starts April 2020; Ensysce trial will be with oral formulation",
         "Product Description": "nafamostat, approved in Japan to treat pancreatitis and other diseases",
         "Clinical Trials for COVID-19": "NCT04352400, NCT04418128",
         "Funder": "Unknown",
         "Published Results": "Critical Care (https://doi.org/10.1186/s13054-020-03078-z)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "OncoImmune": [
      {
         "Developer ": {
            " Researcher": "OncoImmune"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III trial progress report released in June 2020",
         "Product Description": "CD24Fc, biological immunomodulator (nonpolymorphic regions of CD24 attached to the Fc region of human IgG1)",
         "Clinical Trials for COVID-19": "NCT04317040",
         "Funder": "Unknown",
         "Published Results": "(https://www.businesswire.com/news/home/20200614005028/en/OncoImmune-Reports-Progress-Phase-III-Clinical-Trial)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Graft versus Host Disease"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "PharmaMar/ Boryung Pharmaceutical/ Hospitals in Spain": [
      {
         "Developer ": {
            " Researcher": "PharmaMar/ Boryung Pharmaceutical/ Hospitals in Spain"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I trial recruiting July 2020; Trials in Korea to start 3Q 2020",
         "Product Description": "Aplidin (plitidepsin), approved in Australia to treat multiple myeloma",
         "Clinical Trials for COVID-19": "NCT04382066",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "NeuroRx/ Relief Therapeutics/ Thomas Jefferson University Hospital/ NYU Langone Health/ Houston Methodist Hospital": [
      {
         "Developer ": {
            " Researcher": "NeuroRx/ Relief Therapeutics/ Thomas Jefferson University Hospital/ NYU Langone Health/ Houston Methodist Hospital"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "FDA grants Fast Track Designation June 2020; Phase II/III trial started in April 2020; Expanded access protocols",
         "Product Description": "Aviptadil, synthetic form of Vasoactive Intestinal Polypeptide (RLF-100)",
         "Clinical Trials for COVID-19": "NCT04311697, NCT04453839, NCT04360096",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Sarcoid, Pulmonary Fibrosis, Bronchospasm, Erectile Dysfunction, and Acute Respiratory Distress Syndrome (ARDS)"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Apeptico/ Medical University Vienna": [
      {
         "Developer ": {
            " Researcher": "Apeptico/ Medical University Vienna"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trials ongoing July 2020; Individual expanded access in Austria April 2020",
         "Product Description": "solnatide (synthetic molecule with a structure based on the lectin-like domain of human Tumour Necrosis Factor alpha)",
         "Clinical Trials for COVID-19": "EudraCT 2020-001244-26, EudraCT 2017-003855-47",
         "Funder": "EU Commission (Horizon 2020 Program)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Pneumonia, sepsis, ARDS, Primary Graft Dysfunction, and pulmonary dysfunctions"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Panoptes Pharma GmbH": [
      {
         "Developer ": {
            " Researcher": "Panoptes Pharma GmbH"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "PP-001",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Severe eye diseases"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "4D Pharma": [
      {
         "Developer ": {
            " Researcher": "4D Pharma"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II enrolling July 2020",
         "Product Description": "MRx-4DP0004, strain of Bifidobacterium breve isolated from the gut microbiome of a healthy human",
         "Clinical Trials for COVID-19": "NCT04363372, EudraCT 2020-001597-30",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Asthma"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "ARMS Pharmaceutical / UH Cleveland Medical Center / Case Western Reserve University": [
      {
         "Developer ": {
            " Researcher": "ARMS Pharmaceutical / UH Cleveland Medical Center / Case Western Reserve University"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Trial starts April 2020",
         "Product Description": "ARMS-1",
         "Clinical Trials for COVID-19": "",
         "Funder": "Cleveland Foundation",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Influenza prophylaxis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Blade Therapeutics": [
      {
         "Developer ": {
            " Researcher": "Blade Therapeutics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "BLD-2660, synthetic small molecule inhibitor of calpain (CAPN) 1, 2, and 9",
         "Clinical Trials for COVID-19": "NCT04334460",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Laurent Pharmaceuticals": [
      {
         "Developer ": {
            " Researcher": "Laurent Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial recruiting July 2020",
         "Product Description": "LAU-7b (fenretinide)",
         "Clinical Trials for COVID-19": "NCT04417257",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treat exaggerated inflammatory response in adult cystic fibrosis patients"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Institut National de la Sante et de la Recherche Medicale (Merck KGaA)": [
      {
         "Developer ": {
            " Researcher": "Institut National de la Sante et de la Recherche Medicale (Merck KGaA)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III trial recruiting May 2020",
         "Product Description": "Rebif (interferon beta-1a)",
         "Clinical Trials for COVID-19": "EudraCT 2020-000936-23     \n\nNCT04315948",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2002, approved to treat multiple sclerosis",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Chelation Partners": [
      {
         "Developer ": {
            " Researcher": "Chelation Partners"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "DIBI, iron-binding polymer",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "KD Pharma / SLA Pharma": [
      {
         "Developer ": {
            " Researcher": "KD Pharma / SLA Pharma"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "EPAspire, oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Familial adenomatous polyposis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "MediciNova/ Yale\n": [
      {
         "Developer ": {
            " Researcher": "MediciNova/ Yale\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial FDA approved and not yet recruiting July 2020  ",
         "Product Description": "MN-166 (ibudilast), orally bioavailable, small molecule macrophase migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor",
         "Clinical Trials for COVID-19": "NCT04429555",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treatment of numerous neurodegenerative diseases and substance dependence\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "AstraZeneca; ACCORD study \n": [
      {
         "Developer ": {
            " Researcher": "AstraZeneca; ACCORD study \n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Case series results released June 2020; ACCORD Phase II trial to start May 2020",
         "Product Description": "Calquence (acalabrutinib), Bruton's tyrosine kinase (BTK) inhibitor",
         "Clinical Trials for COVID-19": "NCT04346199\n\nNCT04380688",
         "Funder": "UK Government (ACCORD study)\n",
         "Published Results": "Science Immunology (https://immunology.sciencemag.org/content/5/48/eabd0110)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2017, approved to treat mantle cell lymphoma and chronic lymphocytic leukemia",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "CalciMedica": [
      {
         "Developer ": {
            " Researcher": "CalciMedica"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Open label phase II trial top line data released July 2020; Phase II trial recruiting July 2020",
         "Product Description": "Auxora (CM4620-IE), calcium release-activated calcium (CRAC) channel inhibtor",
         "Clinical Trials for COVID-19": "NCT04345614",
         "Funder": "Unknown",
         "Published Results": "CalciMedica (https://www.calcimedica.com/news/calcimedica-announces-positive-topline-data-from-interim-analysis-of-trial-evaluating-auxora-in-patients-with-severe-covid-19-pneumonia)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Pancreatitis"
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Pneumagen Ltd.": [
      {
         "Developer ": {
            " Researcher": "Pneumagen Ltd."
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Neumifil, multivalent carbohydrate binding molecules",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "RedHill Biopharma\n": [
      {
         "Developer ": {
            " Researcher": "RedHill Biopharma\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Preliminary data from individual patient expanded access released in April 2020",
         "Product Description": "Yeliva (opaganib, ABC294640), oral sphingosine kinase-2 (SK2) selective inhibitor\n",
         "Clinical Trials for COVID-19": "NCT04435106, NCT04414618",
         "Funder": "Unknown",
         "Published Results": "RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15258), RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15257), RedHill Biopharma (https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15261), medRxiv (https://doi.org/10.1101/2020.06.20.20099010)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Various oncology indications\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/25/2020"
      }
   ],
   "Moleculin Biotech / University of Texas Medical Branch": [
      {
         "Developer ": {
            " Researcher": "Moleculin Biotech / University of Texas Medical Branch"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "WP1122, glucose decoy prodrug (and related drug candidates)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Swedish Orphan Biovitrum / REMAP-CAP global trial": [
      {
         "Developer ": {
            " Researcher": "Swedish Orphan Biovitrum / REMAP-CAP global trial"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Kineret (anakinra), interleukin-1 receptor antagonist",
         "Clinical Trials for COVID-19": "NCT04324021, NCT02735707, NCT04339712, NCT04330638, NCT04366232, NCT04443881, NCT04462757",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.04.23.20076612), Lancet (https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30164-8/fulltext), medRxiv (https://doi.org/10.1101/2020.06.15.20132407)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2001, approved to treat rheumatoid arthritis and cryopyrin-associated periodic syndromes",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Persephone Biosciences": [
      {
         "Developer ": {
            " Researcher": "Persephone Biosciences"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Clinical trials to start in 2020",
         "Product Description": "Microbiome therapeutic",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/30/2020"
      }
   ],
   "Silkim Pharma": [
      {
         "Developer ": {
            " Researcher": "Silkim Pharma"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Coronzot, a novel family of drugs, sequestration of the labile iron",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/1/2020"
      }
   ],
   "BerGenBio; ACCORD study": [
      {
         "Developer ": {
            " Researcher": "BerGenBio; ACCORD study"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "ACCORD trial started June 2020, top line data expected summer 2020 ",
         "Product Description": "bemcentinib, selective AXL kinase inhibitor",
         "Clinical Trials for COVID-19": "",
         "Funder": "UK Government (ACCORD study)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Various cancers "
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "NanoViricides/ TheraCour Pharma Inc.": [
      {
         "Developer ": {
            " Researcher": "NanoViricides/ TheraCour Pharma Inc."
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "A number of synthesized nanoviricide drug candidates",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Numerous trials with global research sponsors including World Health Organization SOLIDARITY trial; ORCHID trial with National Heart, Lung, and Blood Institute (NHLBI); REMAP-CAP global trial; Novartis; PRINCIPLE trial": [
      {
         "Developer ": {
            " Researcher": "Numerous trials with global research sponsors including World Health Organization SOLIDARITY trial; ORCHID trial with National Heart, Lung, and Blood Institute (NHLBI); REMAP-CAP global trial; Novartis; PRINCIPLE trial"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Prevention studies continue in Asia; NIH study stopped in June 2020; Novartis discontinues trial due to feasibility of recruitment in June 2020; WHO discontinues hydroxychloquine arm in the SOLIDARITY trial July 2020; FDA revoked the March 28, 2020 Emergency Use Authorization on June 15, 2020; RECOVERY trial prelim results released June 2020, trial arm stopped; Univ. of Minnesota trial results released June 2020 ",
         "Product Description": "Chloroquine/ Hydroxychloroquine, antimalarial",
         "Clinical Trials for COVID-19": "Over 50 trials registered at Clinicaltrials.gov, including: NCT04261517, NCT04303507, NCT04303299, NCT04304053, NCT04307693, NCT04316377, NCT04315948, NCT04321993, ECT2020-001113-21, NCT04323527, NCT04333732, NCT04332991, NCT04345419, NCT04341870, NCT04345289, NCT02735707, NCT04351347, NCT04341493, NCT04332094, NCT04349410, NCT04286503, NCT04328012, NCT04346147, NCT04428268",
         "Funder": "COVID-19 Treatment Accelerator (University of Washington/NYU trial and Mahidol Oxford Tropical Medicine Research Unit trial); UK Government (University of Oxford RECOVERY trial and PRINCIPLE trial); Life Arc (PIONEER trial)",
         "Published Results": "NCT04261517 (https://clinicaltrials.gov/ct2/show/NCT04261517?draw=5+%28prelim+outcomes%3F%29), IHU-Méditerranée Infection (https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf), Journal of ZheJiang University (Medical Sciences) (http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.03.03), medRxiv (https://doi.org/10.1101/2020.03.22.20040758), Int'l Journal of Antimicrobial Agents (https://doi.org/10.1016/j.ijantimicag.2020.105949), medRxiv (ChiCTR2000029559) (https://doi.org/10.1101/2020.04.10.20060558), medRxiv (https://doi.org/10.1101/2020.03.22.20040949), medRxiv (https://doi.org/10.1101/2020.04.02.20047050), medRxiv (https://doi.org/10.1101/2020.03.31.20048777), medRxiv (https://doi.org/10.1101/2020.03.24.20042366), medRxiv (NCT04323527) (https://doi.org/10.1101/2020.04.07.20056424), medRxiv (https://doi.org/10.1101/2020.04.08.20057539), medRxiv (https://doi.org/10.1101/2020.04.08.20054551), ScienceDirect (https://www.sciencedirect.com/science/article/pii/S0399077X20300858?via%3Dihub), ISAC (https://www.isac.world/news-and-publications/official-isac-statement), ScienceDirect (https://www.sciencedirect.com/science/article/pii/S0924857920300996), medRxiv (https://doi.org/10.1101/2020.04.10.20060699), medRxiv (ChiCTR2000029868) (https://doi.org/10.1101/2020.04.10.20060558), medRxiv (https://doi.org/10.1101/2020.04.14.20065276), medRxiv (https://doi.org/10.1101/2020.04.16.20065920), medRxiv (https://doi.org/10.1101/2020.04.16.20068205), medRxiv (https://doi.org/10.1101/2020.04.22.20075671), medRxiv (https://doi.org/10.1101/2020.04.21.20066761), medRxiv (https://doi.org/10.1101/2020.04.26.20081059), medRxiv (https://doi.org/10.1101/2020.04.27.20082180), medRxiv (https://doi.org/10.1101/2020.04.27.20073379), medRxiv (https://doi.org/10.1101/2020.04.27.20074583), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2012410), medRxiv (https://doi.org/10.1101/2020.05.02.20080036), medRxiv (https://doi.org/10.1101/2020.05.02.20088872), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2766117), medRxiv (https://doi.org/10.1101/2020.05.07.20093831), medRxiv (https://doi.org/10.1101/2020.05.07.20094326), medRxiv (https://doi.org/10.1101/2020.05.05.20088757), BMJ (https://www.bmj.com/content/369/bmj.m1849), BMJ (https://www.bmj.com/content/369/bmj.m1844), medRxiv (https://doi.org/10.1101/2020.05.14.20101774), medRxiv (https://doi.org/10.1101/2020.05.12.20099028), medRxiv (https://doi.org/10.1101/2020.05.13.20094193), The Lancet (retracted) (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext), Lancet correction (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31249-6/fulltext), Lancet concern (https://www.thelancet.com/journals/lanpub/article/PIIS0140-6736(20)31290-3/fulltext), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2016638), Lancet retraction (https://www.thelancet.com/lancet/article/s0140673620313246), medRxiv (https://doi.org/10.1101/2020.05.18.20066902), medRxiv (https://doi.org/10.1101/2020.05.21.20109207), medRxiv (https://doi.org/10.1101/2020.06.11.20126359), medRxiv (https://doi.org/10.1101/2020.06.05.20123299), medRxiv (https://doi.org/10.1101/2020.06.05.20122705), medRxiv (https://doi.org/10.1101/2020.06.09.20116806), medRxiv (https://doi.org/10.1101/2020.06.10.20101105), medRxiv (https://doi.org/10.1101/2020.06.03.20121558), medRxiv (https://doi.org/10.1101/2020.05.27.20114066), medRxiv (https://doi.org/10.1101/2020.05.28.20114835), medRxiv (https://doi.org/10.1101/2020.06.01.20118901), medRxiv (https://doi.org/10.1101/2020.05.28.20115741), medRxiv (https://doi.org/10.1101/2020.05.19.20106906), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), medRxiv (https://doi.org/10.1101/2020.06.16.20132597), medRxiv (https://doi.org/10.1101/2020.06.17.20133884), medRxiv (https://doi.org/10.1101/2020.06.16.20133066), medRxiv (https://doi.org/10.1101/2020.06.16.20132878), J of Critical Care (https://doi.org/10.1016/j.jcrc.2020.03.005), medRxiv (https://doi.org/10.1101/2020.06.19.20136093), medRxiv (https://doi.org/10.1101/2020.06.19.20135475), medRxiv (https://doi.org/10.1101/2020.06.23.20137992), medRxiv (https://doi.org/10.1101/2020.06.26.20056507), medRxiv (https://doi.org/10.1101/2020.06.24.20139386), WHO (https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19), It'l J Infectious Disease (ttps://doi.org/10.1016/j.ijid.2020.06.099), The Lancet (https://doi.org/10.1016/S0140-6736(20)31528-2)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1949, approved to treat malaria (chloroquine), FDA-approved since at least 1955, approved to treat malaria, rheumatoid arthritis, and lupus (hydroxychloroquine)",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Aarhus University": [
      {
         "Developer ": {
            " Researcher": "Aarhus University"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial ongoing July 2020",
         "Product Description": "senicapoc",
         "Clinical Trials for COVID-19": "EudraCT 2020-001420-34",
         "Funder": "The Danish Government",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Sickle cell anemia; Alzheimer's disease"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Biohaven/ Thomas Jefferson University": [
      {
         "Developer ": {
            " Researcher": "Biohaven/ Thomas Jefferson University"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II/III recruiting July 2020",
         "Product Description": "vazegepant, CGRP receptor antagonist",
         "Clinical Trials for COVID-19": "NCT04346615",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Acute migraine"
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "University of British Columbia/Apeiron Biologics": [
      {
         "Developer ": {
            " Researcher": "University of British Columbia/Apeiron Biologics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II began in April 2020",
         "Product Description": "APN01; recombinant soluble human Angiotensin Converting Enzyme 2",
         "Clinical Trials for COVID-19": "",
         "Funder": "Austrian Government",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Acute lung injury, Acute respiratory distress syndrome, Pulmonary arterial hypertension"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Quotient Sciences/ CytoAgents": [
      {
         "Developer ": {
            " Researcher": "Quotient Sciences/ CytoAgents"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I/II to start in 2020",
         "Product Description": "GP1681, small molecule inhibitor of cytokine release",
         "Clinical Trials for COVID-19": "",
         "Funder": "Richard King Mellon Foundation",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Noveome Biotherapeutics/ Singota Solutions": [
      {
         "Developer ": {
            " Researcher": "Noveome Biotherapeutics/ Singota Solutions"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I/II to start in Q4 2020",
         "Product Description": "ST266, cell-free biologic made from anti-inflammatory proteins secreted by placental cells",
         "Clinical Trials for COVID-19": "",
         "Funder": "Commonwealth of Pennsylvania",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Multiple ophthalmic indications"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "BioAegis Therapeutics Inc.": [
      {
         "Developer ": {
            " Researcher": "BioAegis Therapeutics Inc."
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial not yet recruiting July 2020",
         "Product Description": "recombinant human plasma gelsolin (rhu-pGSN)",
         "Clinical Trials for COVID-19": "NCT04358406",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Community-acquired pneumonia"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "CTI Biopharma": [
      {
         "Developer ": {
            " Researcher": "CTI Biopharma"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III trial recruiting July 2020, results expected by the end of 2020",
         "Product Description": "pacritinib, oral kinase inhibitor with specificity for JAK2, IRAK1 and CSFIR",
         "Clinical Trials for COVID-19": "NCT04404361",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Myelofibrosis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Pharming": [
      {
         "Developer ": {
            " Researcher": "Pharming"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial not yet recruiting July 2020; compassionate use",
         "Product Description": "Ruconest (recombinant human C1 esterase inhibitor)",
         "Clinical Trials for COVID-19": "NCT04414631",
         "Funder": "Unknown",
         "Published Results": "Pharming (https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2014, approved to treat hereditary angioedema",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Algernon Pharmaceuticals": [
      {
         "Developer ": {
            " Researcher": "Algernon Pharmaceuticals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Cerocal (ifenprodil), NP-120, an NDMA receptor glutamate receptor antagonist targeting Glu2NB",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Idiopathic Pulmonary Fibrosis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Eiger BioPharmaceuticals, Inc.": [
      {
         "Developer ": {
            " Researcher": "Eiger BioPharmaceuticals, Inc."
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II began in April 2020",
         "Product Description": "Peginterferon lambda",
         "Clinical Trials for COVID-19": "NCT04331899",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Hepatitis Delta"
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Feinstein Institutes for Medical Research at Northwell Health/ Alchem": [
      {
         "Developer ": {
            " Researcher": "Feinstein Institutes for Medical Research at Northwell Health/ Alchem"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II study underway in April 2020",
         "Product Description": "Pepcid (famotidine), histamine-2 (H2) receptor antagonist",
         "Clinical Trials for COVID-19": "NCT04389567, NCT04370262",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.05.01.20086694), Gastroenterology (10.1053/j.gastro.2020.05.053)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1986, approved to treat ulcers, gastroesophageal reflux disease, erosive esophagitis, pathological hypersecretory conditions, and to reduce the risk of duodenal ulcer recurrence",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Pfizer; other global research sponsors": [
      {
         "Developer ": {
            " Researcher": "Pfizer; other global research sponsors"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Pfizer and other Phase II trial not yet recruiting July 2020",
         "Product Description": "Xeljanz (tofacitinib), Janus kinase (JAK) inhibitor",
         "Clinical Trials for COVID-19": "NCT04332042, NCT04415151, NCT04390061, NCT04412252",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2012, approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Karyopharm Therapeutics": [
      {
         "Developer ": {
            " Researcher": "Karyopharm Therapeutics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial ongoing July 2020",
         "Product Description": "Xpovio (selinexor), oral, selective inhibitor of nuclear export (SINE) compound",
         "Clinical Trials for COVID-19": "NCT04355676, NCT04349098",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treat various cancers"
         },
         "FDA-Approved Indications": "FDA-approved since 2019, approved to treat multiple myeloma",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "pHbarrier": [
      {
         "Developer ": {
            " Researcher": "pHbarrier"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "pH barrier, transepithelial nebulized alkaline treatment",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/30/2020"
      }
   ],
   "Washington University School of Medicine in St. Louis": [
      {
         "Developer ": {
            " Researcher": "Washington University School of Medicine in St. Louis"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial recruiting May 2020",
         "Product Description": "Luvox (fluvoxamine), a selective serotonin reuptake inhibitor",
         "Clinical Trials for COVID-19": "NCT04342663",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1994, approved to treat obsessive compulsive disorder",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/14/2020"
      }
   ],
   "University of Hawaii (Boehringer Ingelheim); other global research sponsors": [
      {
         "Developer ": {
            " Researcher": "University of Hawaii (Boehringer Ingelheim); other global research sponsors"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II Univ. of Hawaii trial started June 2020",
         "Product Description": "Micardis (telmisartan)",
         "Clinical Trials for COVID-19": "NCT04360551, NCT04355936, NCT04359953",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1998, approved to treat hypertension and reduce cardiovascular risk in patients unable to take ACE inhibitors",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Insmed Inc.": [
      {
         "Developer ": {
            " Researcher": "Insmed Inc."
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II study to begin enrollment in May 2020",
         "Product Description": "brensocatib, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1)",
         "Clinical Trials for COVID-19": "EudraCT 2020-001643-13",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Bronchiectasis and other inflammatory diseases"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd (Novaferon) \n": [
      {
         "Developer ": {
            " Researcher": "Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd (Novaferon) \n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Novaferon, Nova, interferon, licensed in China for Hepatitis B",
         "Clinical Trials for COVID-19": "ChiCTR2000029573       \n\nChiCTR2000029496",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.04.24.20077735)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "RedHill Biopharma/ NIAID\n": [
      {
         "Developer ": {
            " Researcher": "RedHill Biopharma/ NIAID\n"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RHB-107 (upamostat, WX-671), serine protease inhibitor",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Various oncology indications\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/8/2020"
      }
   ],
   "Union Therapeutics/ Institute Pasteur Korea/ Daewoong Therapeutics; First Wave Bio ": [
      {
         "Developer ": {
            " Researcher": "Union Therapeutics/ Institute Pasteur Korea/ Daewoong Therapeutics; First Wave Bio "
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Danish Medicines Agency approved a Phase I trial July 2020 (UN9011, Union Therapeutics); Daewoong to apply for Phase I trial in Korea in July 2020",
         "Product Description": "UNI9011 (Union Therapeutics), FW-1022 (First Wave Bio), DWRX2003 (Daewoong) niclosamide",
         "Clinical Trials for COVID-19": "NCT04345419, NCT04399356, NCT04436458, EudraCT 2020-002233-15",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Atopic Dermatitis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "University of Alabama at Birmingham; Leading Biosciences": [
      {
         "Developer ": {
            " Researcher": "University of Alabama at Birmingham; Leading Biosciences"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II recruiting July 2020",
         "Product Description": "Lysteda/Cyklokapron/LB1148 (tranexamic acid), an antifibrinolytic",
         "Clinical Trials for COVID-19": "NCT04338074, NCT04338126, NCT04390217",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1986, approved to treat cyclic heavy menstrual bleeding",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Pulmotect": [
      {
         "Developer ": {
            " Researcher": "Pulmotect"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trials recruiting July 2020",
         "Product Description": "PUL-042 inhalation solution",
         "Clinical Trials for COVID-19": "NCT04312997, NCT04313023",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Prevent and treat respiratory complications in immunosuppressed cancer patients"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Abivax": [
      {
         "Developer ": {
            " Researcher": "Abivax"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase IIb/III trial started July 2020, top line results expected in 2020",
         "Product Description": "ABX464 ",
         "Clinical Trials for COVID-19": "NCT04393038",
         "Funder": "Bpifrance",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Ulcerative colitis; rheumatoid arthritis; hepatocellular carcinoma\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Exvastat Ltd / Global sponsors": [
      {
         "Developer ": {
            " Researcher": "Exvastat Ltd / Global sponsors"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II and Phase III trials recruiting July 2020",
         "Product Description": "Gleevac (imatinib), kinase inhibitor",
         "Clinical Trials for COVID-19": "NCT04346147, NCT04357613, NCT04356495, NCT04422678, NCT04394416",
         "Funder": "Innovative Medicines Initiative",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2001, approved to treat various cancers",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Faron Pharmaceuticals / REMAP-CAP global trial / WHO SOLIDARITY trial/ various global researchers": [
      {
         "Developer ": {
            " Researcher": "Faron Pharmaceuticals / REMAP-CAP global trial / WHO SOLIDARITY trial/ various global researchers"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Results from various trials released June 2020; REMAP-CAP trial recruiting May 2020 ",
         "Product Description": "Traumakine (interferon beta 1-a)",
         "Clinical Trials for COVID-19": "NCT02735707, IRCT20100228003449N28, NCT04350671, NCT04343768, NCT04315948",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.05.28.20116467)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Noxopharm": [
      {
         "Developer ": {
            " Researcher": "Noxopharm"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I started July 2020",
         "Product Description": "Veyonda (idronoxil)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Prostate cancer"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "AstraZeneca/ Saint Luke's Mid America Heart Institute; Cambridge University Hospitals NHS Foundation Trust; TACTIC-E trial studying dapagliflozin + ambrisentan": [
      {
         "Developer ": {
            " Researcher": "AstraZeneca/ Saint Luke's Mid America Heart Institute; Cambridge University Hospitals NHS Foundation Trust; TACTIC-E trial studying dapagliflozin + ambrisentan"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III study started in April 2020 (AstraZeneca)",
         "Product Description": "Farxiga (dapagliflozin), sodium-glucose cotransporter 2 (SGLTs) inhibitor",
         "Clinical Trials for COVID-19": "NCT04350593, NCT04393246",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Heart failure; Chronic kidney disease"
         },
         "FDA-Approved Indications": "FDA-approved since 2014, approved to improve glycemic controls in adults with type 2 diabetes and reduce the risk of hospitalization for heart failure in adults with type 2 diabetes",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/13/2020"
      }
   ],
   "The First Affiliated Hospital of Fujian Medical University/Novartis": [
      {
         "Developer ": {
            " Researcher": "The First Affiliated Hospital of Fujian Medical University/Novartis"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial recruiting May 2020",
         "Product Description": "Gilenya (fingolimod), sphingosine 1-phosphate receptor modulator",
         "Clinical Trials for COVID-19": "NCT04280588",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2010, approved to treat multiple sclerosis",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "BioIncept": [
      {
         "Developer ": {
            " Researcher": "BioIncept"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Preparing for a Phase I/IIa trial in May 2020",
         "Product Description": "sPIF (synthetic pre implantation factor)\n",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/20/2020"
      }
   ],
   "Synairgen / University of Southampton": [
      {
         "Developer ": {
            " Researcher": "Synairgen / University of Southampton"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II began in March 2020; Initial results expected by end of June 2020",
         "Product Description": "SNG001, inhaled formulation of interferon beta-1a",
         "Clinical Trials for COVID-19": "NCT04385095",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Asthma patients with cold or flu infection; COPD patients with viral infections"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Numerous trials with research sponsors globally; University of Oxford RECOVERY trial; REMAP-CAP global trial; Covis Pharma B.V.": [
      {
         "Developer ": {
            " Researcher": "Numerous trials with research sponsors globally; University of Oxford RECOVERY trial; REMAP-CAP global trial; Covis Pharma B.V."
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "RECOVERY trial results released (dexamethasone) June 2020",
         "Product Description": "Methylprednisolone/ ciclesonide (Alvesco)/ hydrocortisone/ corticosteroids",
         "Clinical Trials for COVID-19": "NCT04244591, NCT04263402, NCT04273321, ChiCTR2000029656, ChiCTR2000029386, NCT02735707, NCT04330586, 2020-001113-21, NCT04345445, NCT04349410, NCT04329650",
         "Funder": "UK Government (University of Oxford RECOVERY trial)",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.03.06.20032342), medRxiv (https://doi.org/10.1101/2020.03.28.20045955), medRxiv (https://doi.org/10.1101/2020.04.07.20056390), medRxiv (https://doi.org/10.1101/2020.04.17.20064469), medRxiv (https://doi.org/10.1101/2020.04.17.20069773), medRxiv (https://doi.org/10.1101/2020.04.21.20066258), medRxiv (https://doi.org/10.1101/2020.05.04.20074609), medRxiv (https://doi.org/10.1101/2020.05.08.20094755), medRxiv (https://doi.org/10.1101/2020.05.11.20097709), medRxiv (https://doi.org/10.1101/2020.05.22.20110544), (http://www.ox.ac.uk/news/2020-06-16-low-cost-dexamethasone-reduces-death-one-third-hospitalised-patients-severe), medRxiv (https://doi.org/10.1101/2020.06.15.20132407), medRxiv (https://doi.org/10.1101/2020.06.17.20133579), medRxiv (https://doi.org/10.1101/2020.06.17.20134031), medRxiv (https://doi.org/10.1101/2020.06.19.20135491), medRxiv (https://doi.org/10.1101/2020.06.22.201372730), medRxiv (https://doi.org/10.1101/2020.06.23.20137471), medRxiv (https://doi.org/10.1101/2020.06.19.20109173), medRxiv (https://doi.org/10.1101/2020.06.22.20137273), medRxiv (https://doi.org/10.1101/2020.06.22.20134957), medRxiv (https://doi.org/10.1101/2020.06.22.20133413)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since at least the 1950s, approved to treat many diseases, including anti-iflammatory conditions and some cancers; asthma (ciclesconide)",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      }
   ],
   "National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Nova Scotia Health Authority; Hospital of Prato; University of Colorado (Eli Lilly); TACTIC-R trial": [
      {
         "Developer ": {
            " Researcher": "National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Nova Scotia Health Authority; Hospital of Prato; University of Colorado (Eli Lilly); TACTIC-R trial"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Eli Lilly Phase III trial started June 2020; NIAID trial remdesivir + baricitinib recruiting May 2020",
         "Product Description": "Olumiant (baricitinib), Janus kinase (JAK) inhibitor",
         "Clinical Trials for COVID-19": "NCT04321993, NCT04320277, NCT04340232, NCT04280705, NCT04345289, NCT04346147, NCT04358614, NCT04373044, NCT04438629, NCT04421027, NCT04362943, NCT04393051, NCT04401579, NCT04390464, NCT04399798, NCT04365764",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.06.26.20135319), J Infect (10.1016/j.jinf.2020.04.017)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2018, approved to treat rheumatoid arthritis",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Applied Therapeutics / numerous New York City hospitals": [
      {
         "Developer ": {
            " Researcher": "Applied Therapeutics / numerous New York City hospitals"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II recruiting July 2020; Individual patient expanded access",
         "Product Description": "AT-001, aldose reductase inhibitor",
         "Clinical Trials for COVID-19": "NCT04365699",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Diabetic cardiomyopathy"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Amarin Corp": [
      {
         "Developer ": {
            " Researcher": "Amarin Corp"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Vascepa (icosapent ethyl), a form of eicosapentaenoic acid",
         "Clinical Trials for COVID-19": "NCT04412018, NCT04460651",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA approved since 2012, approved to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina, and reduce triglyceride levels in patients with severe hypertriglyceridemia",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Orpheris\n  (Ashvattha Therapeutics)": [
      {
         "Developer ": {
            " Researcher": "Orpheris\n  (Ashvattha Therapeutics)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "FDA agreed to Phase II June 2020",
         "Product Description": "OP-101, dendrimer-based therapy",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/2/2020"
      }
   ],
   "Resverlogix": [
      {
         "Developer ": {
            " Researcher": "Resverlogix"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "apabetalone (RVX-208), selective BET (bromodomain and extra-terminal) inhibitor",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Treat various conditions "
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/2/2020"
      }
   ],
   "King's College London": [
      {
         "Developer ": {
            " Researcher": "King's College London"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase IV trial recruiting in June 2020",
         "Product Description": "Flarin (lipid ibuprofen)",
         "Clinical Trials for COVID-19": "NCT04334629",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/4/2020"
      }
   ],
   "Various researchers globally, including University of Oxford": [
      {
         "Developer ": {
            " Researcher": "Various researchers globally, including University of Oxford"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "almitrine",
         "Clinical Trials for COVID-19": "NCT04357457, NCT04380727",
         "Funder": "LifeArc (University of Oxford trial)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Various lung diseases including Acute Respiratory Distress Syndrome (ARDS)"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/5/2020"
      }
   ],
   "Vicore Pharma": [
      {
         "Developer ": {
            " Researcher": "Vicore Pharma"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "VP01, Angiotensin II Type 2 receptor activator ",
         "Clinical Trials for COVID-19": "",
         "Funder": "Life Arc ",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Pulmonary fibrosis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/5/2020"
      }
   ],
   "Various researchers worldwide, including Ashford and St Peters Hospital NHS Trust/  Guangdong Uni-Innovation Pharmaceuticals Co., Ltd.": [
      {
         "Developer ": {
            " Researcher": "Various researchers worldwide, including Ashford and St Peters Hospital NHS Trust/  Guangdong Uni-Innovation Pharmaceuticals Co., Ltd."
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "leflunomide, pyrimidine synthesis inhibitor",
         "Clinical Trials for COVID-19": "NCT04361214",
         "Funder": "Life Arc (Ashford and St Peters Hospital NHS Trust/ Guangdong Uni-Innovation Pharmaceuticals Co., Ltd. trial)",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.05.29.20114223) ",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1998, approved to treat rheumatoid arthritis",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Various researchers worldwide, including University College London/ The Francis Crick  Institute (COVASE study)/ I-SPY COVID trial": [
      {
         "Developer ": {
            " Researcher": "Various researchers worldwide, including University College London/ The Francis Crick  Institute (COVASE study)/ I-SPY COVID trial"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III trials recruiting June 2020",
         "Product Description": "Pulmozyme (nebulised dornase alfa), a recombinant DNase enzyme",
         "Clinical Trials for COVID-19": "NCT04409925, NCT04359654, NCT04387786, NCT04355364, NCT04402944, NCT04402970",
         "Funder": "Life Arc (COVASE study)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 1993, approved to treat cystic fibrosis",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Sun\n  Pharmaceutical Industries Ltd": [
      {
         "Developer ": {
            " Researcher": "Sun\n  Pharmaceutical Industries Ltd"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase II trial started June 2020, results expected by October",
         "Product Description": "AQCH, plant-derived (phytopharmaeutical) drug",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/9/2020"
      }
   ],
   "Genentech": [
      {
         "Developer ": {
            " Researcher": "Genentech"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "MSTT1041A (anti-ST2, the receptor for IL-33)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/9/2020"
      },
      {
         "Developer ": {
            " Researcher": "Genentech"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "UTTR1147A (IL-22-Fc)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/9/2020"
      }
   ],
   "Genetic Engineering and Biotechnology Center (CIGB), Cuba": [
      {
         "Developer ": {
            " Researcher": "Genetic Engineering and Biotechnology Center (CIGB), Cuba"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "CIGB-258, immunoregulatory peptide",
         "Clinical Trials for COVID-19": "https://rpcec.sld.cu/ensayos/RPCEC00000313-Sp",
         "Funder": "Ministry of Public Health of Cuba",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.05.27.20110601)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "FSD\n  Pharma": [
      {
         "Developer ": {
            " Researcher": "FSD\n  Pharma"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase I topline results released June 2020",
         "Product Description": "FSD-201 (ultramicronized palmitoylethanolamide)",
         "Clinical Trials for COVID-19": "",
         "Funder": "",
         "Published Results": "(https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Respiratory infections"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/23/2020"
      }
   ],
   "PhaseBio": [
      {
         "Developer ": {
            " Researcher": "PhaseBio"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase 2 trial expected to start dosing end of June 2020 and results in Q4 2020",
         "Product Description": "PB1046, long-acting, sustained release human vasoactive intestinal peptide (VIP) analogue",
         "Clinical Trials for COVID-19": "NCT04433546",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Pulmonary arterial hypertension"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "PTC Therapeutics": [
      {
         "Developer ": {
            " Researcher": "PTC Therapeutics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase 2/3 trial to start in June 2020",
         "Product Description": "PTC299, oral small molecule inhibitor of dihydroorotate dehydrogenase (DHODH)",
         "Clinical Trials for COVID-19": "",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Various oncology indications"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/18/2020"
      }
   ],
   "Dompe farmaceutici (as part of Exscalate4CoV)": [
      {
         "Developer ": {
            " Researcher": "Dompe farmaceutici (as part of Exscalate4CoV)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "raloxifene (Evista), an estrogen agonist/antagonist",
         "Clinical Trials for COVID-19": "",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA approved since 1997, approved to treat osteoporosis and reduce risk of breat cancer in postmenopausal women with osteoporosis",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/22/2020"
      }
   ],
   "Fulcrum\n  Therapeutics": [
      {
         "Developer ": {
            " Researcher": "Fulcrum\n  Therapeutics"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase III trial to begin June 2020",
         "Product Description": "losmapimod, oral selective p38 mitogen activated protein kinase inhibitor",
         "Clinical Trials for COVID-19": "",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Multiple indications, including facioscapulohumeral muscular dystrophy "
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/26/2020"
      }
   ],
   "Applied\n  Biology/ Brown University/ Corpometria Institute": [
      {
         "Developer ": {
            " Researcher": "Applied\n  Biology/ Brown University/ Corpometria Institute"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "dutasteride, anti-androgen",
         "Clinical Trials for COVID-19": "NCT04446429",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA approved since 2001, approved to treat benign prostatic hyperplasia",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/26/2020"
      }
   ],
   "Merck KGaA": [
      {
         "Developer ": {
            " Researcher": "Merck KGaA"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "FDA cleared Phase II trial to begin in June 2020",
         "Product Description": "M5049, small molecule that block the activation of Toll-like receptor (TLR)7 and TLR8",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Various immuology indications"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      }
   ],
   "Eisai": [
      {
         "Developer ": {
            " Researcher": "Eisai"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Added to REMAP-COVID trial in June 2020",
         "Product Description": "Eritoran, TLR-4 antagonist",
         "Clinical Trials for COVID-19": "",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Sepsis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/2/2020"
      }
   ],
   "Zydus Cadila/ Avant Sante Research Center": [
      {
         "Developer ": {
            " Researcher": "Zydus Cadila/ Avant Sante Research Center"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Phase IIb trials approved to start in Mexico July 2020",
         "Product Description": "desidustat, a hypoxia inducible factor prolyl hydroxylase inhibitor",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Chronic Kidney Disease"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/7/2020"
      }
   ],
   "RECOVERY trial and multiple global research sponsors": [
      {
         "Developer ": {
            " Researcher": "RECOVERY trial and multiple global research sponsors"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "azithromycin, antibiotic",
         "Clinical Trials for COVID-19": "Over 100 clinical trials registered at clinicaltrials.gov",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA approved since at least 2005; approved to treat or prevent bacterial infections",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   " I-SPY COVID Trial (Allergan)": [
      {
         "Developer ": {
            " Researcher": " I-SPY COVID Trial (Allergan)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Cenicriviroc, chemokine receptor 2 and 5 dual antagonist",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Non-Alcoholic SteatoHepatitis (NASH)"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   " I-SPY COVID Trial (Takeda)": [
      {
         "Developer ": {
            " Researcher": " I-SPY COVID Trial (Takeda)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Firazyr (icatibant), bradykinin B2 antagonist",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA approved since 2011, approved to treat hereditary angioedema ",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   " I-SPY COVID Trial (Aerpio Pharmaceuticals)": [
      {
         "Developer ": {
            " Researcher": " I-SPY COVID Trial (Aerpio Pharmaceuticals)"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Razoprotafib,\n  Tie 2 activating compound (AKB-9778)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Lupa Bio, Inc.": [
      {
         "Developer ": {
            " Researcher": "Lupa Bio, Inc."
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Other",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Plans to sumit an IND in 2020",
         "Product Description": "New drug based on a sugar found in human milk",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Baxter": [
      {
         "Developer ": {
            " Researcher": "Baxter"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Device",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "FDA issued an Emergency Use Authorization on April 23, 2020",
         "Product Description": "Oxiris Blood Purification Filter",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/24/2020"
      }
   ],
   "Bellerophon": [
      {
         "Developer ": {
            " Researcher": "Bellerophon"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Device",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Individual patient expanded access",
         "Product Description": "INOpulse",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "ExThera Medical": [
      {
         "Developer ": {
            " Researcher": "ExThera Medical"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Device",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "DOD to fund a multi-center trial June 2020; FDA issued an Emergency Use Authorization on April 17, 2020",
         "Product Description": "Seraph100MicrobindAffinity Blood Filter (Seraphy 100), approved in the EU for pathogen reduction",
         "Clinical Trials for COVID-19": "",
         "Funder": "US Department of Defense (DOD)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "CytoSorbents Corporation": [
      {
         "Developer ": {
            " Researcher": "CytoSorbents Corporation"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Device",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Individual patient expanded access; FDA issued an Emergency Use Authorization on April 10, 2020",
         "Product Description": "CytoSorb (blood purification device, extracorporeal cytokine adsorber))",
         "Clinical Trials for COVID-19": "NCT04324528 ChiCTR2000030475 NCT04344080 DRKS00021447 NCT04385771",
         "Funder": "Unknown",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.06.28.20133561)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/1/2020"
      }
   ],
   "ALung Technologies": [
      {
         "Developer ": {
            " Researcher": "ALung Technologies"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Device",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "FDA issued an Emergency Use Authorization on April 24, 2020",
         "Product Description": "Hemolung Respiratory Assist System",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Acute Exacerbation of Chronic Obstructive Pulmonary Disease; Acute Respiratory Distress Syndrome (ARDS)"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      }
   ],
   "Terumo BCT Inc / Marker Therapeutics AG": [
      {
         "Developer ": {
            " Researcher": "Terumo BCT Inc / Marker Therapeutics AG"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Device",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "FDA issued an Emergency Use Authorization on April 9, 2020",
         "Product Description": "Extracorporeal blood purification (EBP) devices",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Fresenius Medical": [
      {
         "Developer ": {
            " Researcher": "Fresenius Medical"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Device",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "FDA issued an Emergency Use Authorization on April 30, 2020",
         "Product Description": "MultiFiltrate PRO System and multiBic/multiPlus Solutions, continuous renal replacement therapy (CRRT)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/8/2020"
      }
   ],
   "Abiomed": [
      {
         "Developer ": {
            " Researcher": "Abiomed"
         },
         "Treatment vs. Vaccine": "Treatment",
         "Product Category": "Device",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "FDA issued an Emergency Use Authorization on May 29, 2020",
         "Product Description": "Impella RP heart pump",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2017, approved to treat advanced heart failure",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/5/2020"
      }
   ],
   "Scancell/ University of Nottingham/ Nottingham Trent University": [
      {
         "Developer ": {
            " Researcher": "Scancell/ University of Nottingham/ Nottingham Trent University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start in Q1 2021",
         "Product Description": "DNA plasmid vaccine RBD&N",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for cancer"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Entos Pharmaceuticals/ Cytiva": [
      {
         "Developer ": {
            " Researcher": "Entos Pharmaceuticals/ Cytiva"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I/II to start in late July 2020 ",
         "Product Description": "DNA; Covigenix",
         "Clinical Trials for COVID-19": "",
         "Funder": "Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/1/2020"
      }
   ],
   "BioNet Asia": [
      {
         "Developer ": {
            " Researcher": "BioNet Asia"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "DNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/20/2020"
      }
   ],
   "Inovio Pharmaceuticals/Beijing Advaccine Biotechnology/VGXI Inc./ Richter-Helm BioLogics/Ology Bioservices": [
      {
         "Developer ": {
            " Researcher": "Inovio Pharmaceuticals/Beijing Advaccine Biotechnology/VGXI Inc./ Richter-Helm BioLogics/Ology Bioservices"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Phase I",
         "Anticipated Next Steps": "Phase I initial data released June 30, 2020; Phase II/III trials start July/August 2020 ",
         "Product Description": "DNA plasmid vaccine with electroporation; INO-4800",
         "Clinical Trials for COVID-19": "NCT04336410, NCT04447781",
         "Funder": "Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense",
         "Published Results": "Inovio (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as multiple vaccine candidates"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/6/2020"
      }
   ],
   "Mediphage Bioceuticals/ University of Waterloo": [
      {
         "Developer ": {
            " Researcher": "Mediphage Bioceuticals/ University of Waterloo"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "msDNA vaccine",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Symvivo": [
      {
         "Developer ": {
            " Researcher": "Symvivo"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "bacTRL-Spike\n",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/12/2020"
      }
   ],
   "Takis/ Applied DNA Sciences/ Evvivax": [
      {
         "Developer ": {
            " Researcher": "Takis/ Applied DNA Sciences/ Evvivax"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Animal results released in May 2020; Phase I to start in fall 2020",
         "Product Description": "DNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Immunomic Therapeutics / EpiVax / PharmaJet": [
      {
         "Developer ": {
            " Researcher": "Immunomic Therapeutics / EpiVax / PharmaJet"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "DNA plasmid, needle-free delivery",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for SARS"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Zydus Cadila Healthcare Limited ": [
      {
         "Developer ": {
            " Researcher": "Zydus Cadila Healthcare Limited "
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I/II to start in July 2020 ",
         "Product Description": "DNA plasmid",
         "Clinical Trials for COVID-19": "CTRI/2020/07/026352",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      },
      {
         "Developer ": {
            " Researcher": "Zydus Cadila Healthcare Limited "
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Replicating viral vector; measles vector",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "OPENCORONA - Cobra Biologics / Karolinska Institute": [
      {
         "Developer ": {
            " Researcher": "OPENCORONA - Cobra Biologics / Karolinska Institute"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start in 2020",
         "Product Description": "DNA with electroporation",
         "Clinical Trials for COVID-19": "",
         "Funder": "European Commission (Horizon 2020 Program)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/19/2020"
      }
   ],
   "Osaka University/ AnGes/ Takara Bio/ Cytiva": [
      {
         "Developer ": {
            " Researcher": "Osaka University/ AnGes/ Takara Bio/ Cytiva"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start in July 2020",
         "Product Description": "DNA plasmid",
         "Clinical Trials for COVID-19": "NCT04463472",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/13/2020"
      }
   ],
   "Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex": [
      {
         "Developer ": {
            " Researcher": "Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Phase I",
         "Anticipated Next Steps": "Phase I to start in July 2020",
         "Product Description": "DNA vaccine (GX-19)",
         "Clinical Trials for COVID-19": "NCT04445389",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/1/2020"
      }
   ],
   "Chula Vaccine Research Center": [
      {
         "Developer ": {
            " Researcher": "Chula Vaccine Research Center"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "DNA with electroporation",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/18/2020"
      }
   ],
   "National\n  Research Centre, Egypt": [
      {
         "Developer ": {
            " Researcher": "National\n  Research Centre, Egypt"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "DNA plasmid vaccine S, S1, S2, RBD & N",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      },
      {
         "Developer ": {
            " Researcher": "National\n  Research Centre, Egypt"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Influenza A H1N1 vector",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      },
      {
         "Developer ": {
            " Researcher": "National\n  Research Centre, Egypt"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein Subunit S, N, M & S1 protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      }
   ],
   "Ege University": [
      {
         "Developer ": {
            " Researcher": "Ege University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "DNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Statens Serum Institute, Denmark": [
      {
         "Developer ": {
            " Researcher": "Statens Serum Institute, Denmark"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "DNA-based",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I is expected to start in late 2020 or early 2021",
         "Product Description": "DNA plasmid, CoVAXIX",
         "Clinical Trials for COVID-19": "",
         "Funder": "Statens Serum Institute, Denmark",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Valneva/ Dynavax": [
      {
         "Developer ": {
            " Researcher": "Valneva/ Dynavax"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Inactivated (Inactivated + CpG 1018), VLA2001",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for Japanese Encephalitis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Beijing Institute of Biological Products/ Sinopharm": [
      {
         "Developer ": {
            " Researcher": "Beijing Institute of Biological Products/ Sinopharm"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Phase II",
         "Anticipated Next Steps": "In Phase II, June 2020",
         "Product Description": "Inactivated",
         "Clinical Trials for COVID-19": "ChiCTR2000032459",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/12/2020"
      }
   ],
   "Wuhan Institute of Biological Products/ Sinopharm": [
      {
         "Developer ": {
            " Researcher": "Wuhan Institute of Biological Products/ Sinopharm"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Phase II",
         "Anticipated Next Steps": "Phase III trial approved to start in United Arab Emirates June 2020; Early Phase I/II trial results released June 2020",
         "Product Description": "Inactivated",
         "Clinical Trials for COVID-19": " ChiCTR2000031809",
         "Funder": "Unknown",
         "Published Results": "(https://www.cnbg.com.cn/content/details_12_5545.html)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/25/2020"
      }
   ],
   "Research Institute for Biological Safety Problems, Republic of Kazakhstan": [
      {
         "Developer ": {
            " Researcher": "Research Institute for Biological Safety Problems, Republic of Kazakhstan"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Inactivated",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/19/2020"
      }
   ],
   "Institute of Medical Biology, Chinese Academy of Medical Sciences": [
      {
         "Developer ": {
            " Researcher": "Institute of Medical Biology, Chinese Academy of Medical Sciences"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Phase II",
         "Anticipated Next Steps": "Phase II began June 2020",
         "Product Description": "Inactivated",
         "Clinical Trials for COVID-19": "NCT04412538",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/23/2020"
      }
   ],
   "Sinovac/ Dynavax": [
      {
         "Developer ": {
            " Researcher": "Sinovac/ Dynavax"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Inactivated (inactivated + CpG 1018)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      }
   ],
   "Osaka University / BIKEN / NIBIOHN": [
      {
         "Developer ": {
            " Researcher": "Osaka University / BIKEN / NIBIOHN"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Inactivated",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Sinovac/ Instituto Butantan": [
      {
         "Developer ": {
            " Researcher": "Sinovac/ Instituto Butantan"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Phase II",
         "Anticipated Next Steps": "Phase III enrolling in Brazil in July 2020; Phase II started in June 2020; preliminary results from Phase I/II trials released June 2020",
         "Product Description": "Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc)",
         "Clinical Trials for COVID-19": "NCT04456595, NCT04352608, NCT04383574",
         "Funder": "Unknown",
         "Published Results": "(http://www.sinovac.com/?optionid=754&auto_id=904)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for SARS"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Beijing Minhai Biotechnology Co., Ltd.": [
      {
         "Developer ": {
            " Researcher": "Beijing Minhai Biotechnology Co., Ltd."
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Inactivated",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/27/2020"
      }
   ],
   "National Research Centre, Egypt": [
      {
         "Developer ": {
            " Researcher": "National Research Centre, Egypt"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Inactivated whole virus",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      }
   ],
   "KM Biologics": [
      {
         "Developer ": {
            " Researcher": "KM Biologics"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Inactivated (inactivated + alum)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for JE, Zika"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Selcuk University": [
      {
         "Developer ": {
            " Researcher": "Selcuk University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Inactivated",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      },
      {
         "Developer ": {
            " Researcher": "Selcuk University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "mRNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Bharat Biotech": [
      {
         "Developer ": {
            " Researcher": "Bharat Biotech"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Inactivated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Whole-Virion Inactivated",
         "Clinical Trials for COVID-19": "CTRI/2020/07/026300",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/13/2020"
      }
   ],
   "Indian Immunologicals Ltd/ Griffith University": [
      {
         "Developer ": {
            " Researcher": "Indian Immunologicals Ltd/ Griffith University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Live attenuated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Codon deoptimized live attenuated virus",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      }
   ],
   "Codagenix / Serum Institute of India": [
      {
         "Developer ": {
            " Researcher": "Codagenix / Serum Institute of India"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Live attenuated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Animal data in summer 2020",
         "Product Description": "Codon deoptimized live attenuated virus",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV "
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      }
   ],
   "Meissa Vaccines ": [
      {
         "Developer ": {
            " Researcher": "Meissa Vaccines "
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Live attenuated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase 1 beginning of 2021",
         "Product Description": "MV-014-210",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for RSV"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/2/2020"
      }
   ],
   "Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.": [
      {
         "Developer ": {
            " Researcher": "Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S."
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Live attenuated virus",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Codon deoptimized live attenuated vaccines",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "University of Manitoba": [
      {
         "Developer ": {
            " Researcher": "University of Manitoba"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Non-replicating viral vector; dendritic cell-based vaccine",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/20/2020"
      }
   ],
   "Greffex": [
      {
         "Developer ": {
            " Researcher": "Greffex"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Non-replicating viral vector; Ad5 S (GREVAX™ platform)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for MERS\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "ReiThera/ Leukocare/ Univercells": [
      {
         "Developer ": {
            " Researcher": "ReiThera/ Leukocare/ Univercells"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase I in summer 2020",
         "Product Description": "Non-replicating viral vector; replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/19/2020"
      }
   ],
   "Stabilitech Biopharma Ltd": [
      {
         "Developer ": {
            " Researcher": "Stabilitech Biopharma Ltd"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Oral Ad5 S",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "Bharat Biotech/ Thomas Jefferson University": [
      {
         "Developer ": {
            " Researcher": "Bharat Biotech/ Thomas Jefferson University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Recombinant deactivated rabies virus containing S1",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "GeoVax / BravoVax": [
      {
         "Developer ": {
            " Researcher": "GeoVax / BravoVax"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Non-replicating viral vector; MVA encoded VLP",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for LASV, EBOV, MARV, HIV"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "CanSino Biologics/Beijing Institute of Biotechnology/ Canada's National Research Council ": [
      {
         "Developer ": {
            " Researcher": "CanSino Biologics/Beijing Institute of Biotechnology/ Canada's National Research Council "
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Phase II",
         "Anticipated Next Steps": "Approved for military use in China on June 25, 2020; Phase II started April 2020; initial results released May 2020",
         "Product Description": "Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)",
         "Clinical Trials for COVID-19": "NCT04313127 ChiCTR2000030906 ChiCTR2000031781 NCT04398147",
         "Funder": "Unknown",
         "Published Results": "The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for EBOV  "
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Altimmune / University of Alabama at Birmingham": [
      {
         "Developer ": {
            " Researcher": "Altimmune / University of Alabama at Birmingham"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I trial to begin Q3 2020",
         "Product Description": "AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for influenza"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "DZIF - German Center for Infection Research/ IDT Biologika GmbH": [
      {
         "Developer ": {
            " Researcher": "DZIF - German Center for Infection Research/ IDT Biologika GmbH"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Non-replicating viral vector; MVA-S encoded",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for many pathogens"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "ImmunityBio/ NantKwest": [
      {
         "Developer ": {
            " Researcher": "ImmunityBio/ NantKwest"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase I in June 2020; vaccine to be included in US Operation Warp Speed trials according to company",
         "Product Description": "Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for flu, Chik, Zika, EBOV, LASV, HIV/SIV, cancer"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Valo Therapeutics Ltd": [
      {
         "Developer ": {
            " Researcher": "Valo Therapeutics Ltd"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Adenovirus-based + HLA-matched peptides (Pan-Corona)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "Centro Nacional Biotecnologia (CNB-CSIC), Spain": [
      {
         "Developer ": {
            " Researcher": "Centro Nacional Biotecnologia (CNB-CSIC), Spain"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Non-replicating viral vector, MVA expressing structural proteins",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      },
      {
         "Developer ": {
            " Researcher": "Centro Nacional Biotecnologia (CNB-CSIC), Spain"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RNA; Replicating defective SARS-CoV-2 derived RNAs",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent": [
      {
         "Developer ": {
            " Researcher": "Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Will join US Operation Warp Speed vaccine trials in September 2020; Start Phase I/IIa July 2020",
         "Product Description": "Ad26.COV2-S, Non replicating viral vector; Ad26 (alone or with MVA boost)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for Ebola, HIV, RSV"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/7/2020"
      }
   ],
   "Vaxart / Emergent BioSolutions": [
      {
         "Developer ": {
            " Researcher": "Vaxart / Emergent BioSolutions"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I trial to begin in the second half of 2020",
         "Product Description": "Non-replicating viral vector; Oral Vaccine\n platform",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "University of Georgia/ University of Iowa": [
      {
         "Developer ": {
            " Researcher": "University of Georgia/ University of Iowa"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for MERS "
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      }
   ],
   "Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, and AstraZeneca ": [
      {
         "Developer ": {
            " Researcher": "Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, and AstraZeneca "
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Phase III",
         "Anticipated Next Steps": "Phase III enrolling in Brazil end of June 2020; South African trial starts end of June 2020; Will join US Operation Warp Speed Phase III vaccine trials in August 2020; Phase II/III trials enrolling May 2020",
         "Product Description": "Non-replicating viral vector; AZD 1222 (formerly ChAdOx1)",
         "Clinical Trials for COVID-19": "ISRCTN89951424, NCT04324606, EudraCT 2020-001072-15, EudraCT 2020-001228-32, NCT04400838, ISRCTN89951424, PACTR202006922165132",
         "Funder": "Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/6/2020"
      }
   ],
   "IDIBAPS- Hospital Clinic, Spain": [
      {
         "Developer ": {
            " Researcher": "IDIBAPS- Hospital Clinic, Spain"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "MVA-S",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/1/2020"
      },
      {
         "Developer ": {
            " Researcher": "IDIBAPS- Hospital Clinic, Spain"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "mRNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/1/2020"
      }
   ],
   "National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand": [
      {
         "Developer ": {
            " Researcher": "National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/1/2020"
      }
   ],
   "Grousbeck Gene Therapy Center at Mass. Eye and Ear/ AveXis, a Novartis Company/  Viralgen/ Aldevron/ Catalent/ Penn Medicine": [
      {
         "Developer ": {
            " Researcher": "Grousbeck Gene Therapy Center at Mass. Eye and Ear/ AveXis, a Novartis Company/  Viralgen/ Aldevron/ Catalent/ Penn Medicine"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase 1 to begin second half of 2020",
         "Product Description": "AAVCOVID, Adeno-associated viral vector (AAV), spike protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/2/2020"
      }
   ],
   "Gamaleya  Research Institute": [
      {
         "Developer ": {
            " Researcher": "Gamaleya  Research Institute"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Phase I",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Adeno-based",
         "Clinical Trials for COVID-19": "NCT04437875",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/23/2020"
      }
   ],
   "ID Pharma": [
      {
         "Developer ": {
            " Researcher": "ID Pharma"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Sendai virus vector",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Ankara University": [
      {
         "Developer ": {
            " Researcher": "Ankara University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Non-replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Adenovirus-based",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing": [
      {
         "Developer ": {
            " Researcher": "Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit (gp-96 backbone)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/9/2020"
      }
   ],
   "Sanofi Pasteur / GSK": [
      {
         "Developer ": {
            " Researcher": "Sanofi Pasteur / GSK"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I/II to start in September 2020",
         "Product Description": "Protein subunit; S protein, baculovirus production",
         "Clinical Trials for COVID-19": "",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/8/2020"
      }
   ],
   "iBio / CC-Pharming": [
      {
         "Developer ": {
            " Researcher": "iBio / CC-Pharming"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; Subunit protein, plant produced",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "ImmunoPrecise/ LiteVax BV": [
      {
         "Developer ": {
            " Researcher": "ImmunoPrecise/ LiteVax BV"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Spike-based (epitope screening)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Novavax/ Emergent BioSolutions/ Praha Vaccines/Serum Institute of India/ AGC Biologics": [
      {
         "Developer ": {
            " Researcher": "Novavax/ Emergent BioSolutions/ Praha Vaccines/Serum Institute of India/ AGC Biologics"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Phase I",
         "Anticipated Next Steps": "Will join US Operation Warp Speed vaccine trials, Phase III trial to start in fall 2020; Phase I/II started May 2020; top-line data expected July 2020",
         "Product Description": "Protein subunit; Full-length recombinant SARS COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M (NVX-CoV2373)",
         "Clinical Trials for COVID-19": "NCT04368988",
         "Funder": "Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma": [
      {
         "Developer ": {
            " Researcher": "Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Phase I",
         "Anticipated Next Steps": "Phase I trial started July 2020",
         "Product Description": "Protein subunit; recombinant spike protein with Advax adjuvant (COVAX-19)",
         "Clinical Trials for COVID-19": "NCT04453852",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/10/2020"
      }
   ],
   "National Institute of Infectious Disease, Japan": [
      {
         "Developer ": {
            " Researcher": "National Institute of Infectious Disease, Japan"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit, S protein + adjuvant",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for Influenza"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "ExpreS2ion": [
      {
         "Developer ": {
            " Researcher": "ExpreS2ion"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit, drosophila S2 insect cell expression system VLPs",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "LakePharma, Inc.": [
      {
         "Developer ": {
            " Researcher": "LakePharma, Inc."
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit, nanoparticle vaccine",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "Axon Neuroscience SE": [
      {
         "Developer ": {
            " Researcher": "Axon Neuroscience SE"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Peptides derived from Spike protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/12/2020"
      }
   ],
   "Medigen Vaccine Biologics Corp/ NIAID/ Dynavax": [
      {
         "Developer ": {
            " Researcher": "Medigen Vaccine Biologics Corp/ NIAID/ Dynavax"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "S-2 P protein + CpG 1018",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/12/2020"
      }
   ],
   "Baylor College of Medicine": [
      {
         "Developer ": {
            " Researcher": "Baylor College of Medicine"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; S1 or RBD protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for SARS"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Innovax / Xiamen University / GSK": [
      {
         "Developer ": {
            " Researcher": "Innovax / Xiamen University / GSK"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; COVID-19 XWG-03 truncated Spike proteins",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for HPV  \n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Quadram Institute Biosciences": [
      {
         "Developer ": {
            " Researcher": "Quadram Institute Biosciences"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "OMV-based vaccine",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for Flu A, plaque\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/12/2020"
      }
   ],
   "Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences": [
      {
         "Developer ": {
            " Researcher": "Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase II to start as early as July 2020; Phase I preliminary results expected in September 2020; Received approval to launch clinical trials in China in June 2020",
         "Product Description": "Adjuvanted recombinant protein (RBD-Dimer)",
         "Clinical Trials for COVID-19": "NCT04445194",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for MERS"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Yisheng Biopharma": [
      {
         "Developer ": {
            " Researcher": "Yisheng Biopharma"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit, recombinant protein  ",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "University of California, San Diego": [
      {
         "Developer ": {
            " Researcher": "University of California, San Diego"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch",
         "Clinical Trials for COVID-19": "",
         "Funder": "National Science Foundation (Rapid Response Research [RAPID] grant)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      }
   ],
   "Intravacc/Epivax": [
      {
         "Developer ": {
            " Researcher": "Intravacc/Epivax"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Outer Membrane Vesicle (OMV)-peptide",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/19/2020"
      },
      {
         "Developer ": {
            " Researcher": "Intravacc/Epivax"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Outer Membrane Vesicle (OMV)-subunit",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/12/2020"
      }
   ],
   "AJ Vaccines": [
      {
         "Developer ": {
            " Researcher": "AJ Vaccines"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; S protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "VIDO-InterVac, University of Saskatchewan": [
      {
         "Developer ": {
            " Researcher": "VIDO-InterVac, University of Saskatchewan"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Animal testing results expected in April 2020",
         "Product Description": "Protein subunit, adjuvanted microsphere peptide",
         "Clinical Trials for COVID-19": "",
         "Funder": "The Government of Saskatchewan and the Canadian Federal Government",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "MIGAL Galilee Research Institute": [
      {
         "Developer ": {
            " Researcher": "MIGAL Galilee Research Institute"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; oral E. coli-based protein expression system of S and N proteins",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Biological E Ltd": [
      {
         "Developer ": {
            " Researcher": "Biological E Ltd"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; adjuvanted protein subunit (RBD)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "OncoGen": [
      {
         "Developer ": {
            " Researcher": "OncoGen"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit, synthetic long peptide vaccine candidate for S and M proteins",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "University of Cambridge / DIOSynVax": [
      {
         "Developer ": {
            " Researcher": "University of Cambridge / DIOSynVax"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start as early as June 2020",
         "Product Description": "Protein subunit; S protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Influenza, Ebola"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo": [
      {
         "Developer ": {
            " Researcher": "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; peptide vaccine",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for Ebola"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      },
      {
         "Developer ": {
            " Researcher": "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; subunit vaccine",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      },
      {
         "Developer ": {
            " Researcher": "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Replicating viral vector; measles vector",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      },
      {
         "Developer ": {
            " Researcher": "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Replicating viral vector; VSV vector",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      },
      {
         "Developer ": {
            " Researcher": "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for influenza"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      },
      {
         "Developer ": {
            " Researcher": "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RNA; mRNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      }
   ],
   "Applied Biotechnology Institute, Inc.": [
      {
         "Developer ": {
            " Researcher": "Applied Biotechnology Institute, Inc."
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Orally delivered, heat stable subunit",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/12/2020"
      }
   ],
   "University of Alberta": [
      {
         "Developer ": {
            " Researcher": "University of Alberta"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; spike based",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for Hepatitis C"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "St. Petersburg Scientific Research Institute of Vaccines and Serums": [
      {
         "Developer ": {
            " Researcher": "St. Petersburg Scientific Research Institute of Vaccines and Serums"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)/ Bavarian Nordic": [
      {
         "Developer ": {
            " Researcher": "PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)/ Bavarian Nordic"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to begin by February 2021",
         "Product Description": "Protein subunit, capsid-like particle (CLP)",
         "Clinical Trials for COVID-19": "",
         "Funder": "European Commission (Horizon 2020 Program)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for HPV  "
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/14/2020"
      }
   ],
   "Clover Biopharmaceuticals Inc./ GSK/ Dynavax": [
      {
         "Developer ": {
            " Researcher": "Clover Biopharmaceuticals Inc./ GSK/ Dynavax"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Phase I",
         "Anticipated Next Steps": "CEPI partnership expanded in July 2020, Phase I trial started June 2020, preliminary results expected August 2020",
         "Product Description": "Protein subunit, native like trimeric subunit spike protein",
         "Clinical Trials for COVID-19": "NCT04405908",
         "Funder": "Coalition for Epidemic Preparedness (CEPI)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for HIV, RSV, Influenza"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "WRAIR / USAMRIID": [
      {
         "Developer ": {
            " Researcher": "WRAIR / USAMRIID"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; S protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Flow Pharma": [
      {
         "Developer ": {
            " Researcher": "Flow Pharma"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit, peptide",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer "
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Neovii/Tel Aviv University": [
      {
         "Developer ": {
            " Researcher": "Neovii/Tel Aviv University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RBD-based",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/19/2020"
      }
   ],
   "EpiVax / University of Georgia": [
      {
         "Developer ": {
            " Researcher": "EpiVax / University of Georgia"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; S protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for Inf H7N9"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Generex / EpiVax": [
      {
         "Developer ": {
            " Researcher": "Generex / EpiVax"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; Ii-Key peptide",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for HIV, SARS-CoV, Influenza"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Vaxil Bio": [
      {
         "Developer ": {
            " Researcher": "Vaxil Bio"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit; peptide",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "BiOMVis Srl/ University of Trento": [
      {
         "Developer ": {
            " Researcher": "BiOMVis Srl/ University of Trento"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "OMV-based vaccine",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/12/2020"
      }
   ],
   "University of Pittsburgh": [
      {
         "Developer ": {
            " Researcher": "University of Pittsburgh"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start as early as June 2020",
         "Product Description": "PittCoVacc, Protein subunit, microneedle arrays S1 subunit",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for MERS"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan": [
      {
         "Developer ": {
            " Researcher": "Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit, VLP-recombinant protein + adjuvant",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "University of Queensland / GSK / Dynavax/ CSL": [
      {
         "Developer ": {
            " Researcher": "University of Queensland / GSK / Dynavax/ CSL"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Phase I",
         "Anticipated Next Steps": "Phase I trial started July 2020",
         "Product Description": "Protein subunit; molecular clamp stabilized Spike protein",
         "Clinical Trials for COVID-19": "ACTRN12620000674932p",
         "Funder": "Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Vabiotech": [
      {
         "Developer ": {
            " Researcher": "Vabiotech"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit, recombinant S protein in IC-BEVS  ",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "AnyGo Technology": [
      {
         "Developer ": {
            " Researcher": "AnyGo Technology"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit, recombinant S1-Fc fusion protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "UMN Pharma (Shionogi)": [
      {
         "Developer ": {
            " Researcher": "UMN Pharma (Shionogi)"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start by end of 2020",
         "Product Description": "Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology",
         "Clinical Trials for COVID-19": "",
         "Funder": "Japan Agency for Medical Research and Development",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/10/2020"
      }
   ],
   "IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada": [
      {
         "Developer ": {
            " Researcher": "IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase I testing by summer 2020",
         "Product Description": "Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "EpiVax ": [
      {
         "Developer ": {
            " Researcher": "EpiVax "
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit EPV-CoV-19",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/27/2020"
      }
   ],
   "Lomonosov Moscow State University": [
      {
         "Developer ": {
            " Researcher": "Lomonosov Moscow State University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Structurally modified spherical particles of the tobacco mosaic virus (TMV)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/27/2020"
      }
   ],
   "Kentucky BioProcessing (British American Tobacco)": [
      {
         "Developer ": {
            " Researcher": "Kentucky BioProcessing (British American Tobacco)"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RBD-based",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/27/2020"
      }
   ],
   "Chulalongkorn University/ GPO, Thailand": [
      {
         "Developer ": {
            " Researcher": "Chulalongkorn University/ GPO, Thailand"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RBD protein fused with Fc of IgG + Adjuvant",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/1/2020"
      }
   ],
   "PDS Biotechnology": [
      {
         "Developer ": {
            " Researcher": "PDS Biotechnology"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "PDS-0203; Versamune T-cell activating technology ",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccines against cancers, HBV, influenza, and tuberculosis"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/2/2020"
      }
   ],
   "Verndari/ University of California, Davis": [
      {
         "Developer ": {
            " Researcher": "Verndari/ University of California, Davis"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start summer 2020",
         "Product Description": "Spike protein; VaxiPatch microneedle array dermal patch",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccines against influenza"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/2/2020"
      }
   ],
   "Max-Planck Institute of Colloids and Interfaces": [
      {
         "Developer ": {
            " Researcher": "Max-Planck Institute of Colloids and Interfaces"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Targeted (Langerhans cell specific) protein subunit; spike based",
         "Clinical Trials for COVID-19": "",
         "Funder": "KHAN-1 Technology Transfer Fund I GmbH & Co KG",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/2/2020"
      }
   ],
   "MOGAM Institute for Biomedical Research, GC Pharma": [
      {
         "Developer ": {
            " Researcher": "MOGAM Institute for Biomedical Research, GC Pharma"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/5/2020"
      }
   ],
   "University of San Martin and CONICET, Argentina": [
      {
         "Developer ": {
            " Researcher": "University of San Martin and CONICET, Argentina"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/12/2020"
      }
   ],
   "Baiya Phytopharm/ Chula Vaccine Research Center": [
      {
         "Developer ": {
            " Researcher": "Baiya Phytopharm/ Chula Vaccine Research Center"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Plant-based subunit (RBD-Fc + Adjuvant)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/18/2020"
      }
   ],
   "Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria": [
      {
         "Developer ": {
            " Researcher": "Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Subunit",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      }
   ],
   "University of Virginia": [
      {
         "Developer ": {
            " Researcher": "University of Virginia"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "S subunit intranasal liposomal formulation with GLA/3M052 adjs.",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Izmir Biomedicine and Genome Center": [
      {
         "Developer ": {
            " Researcher": "Izmir Biomedicine and Genome Center"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Recombinant S protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Bogazici University": [
      {
         "Developer ": {
            " Researcher": "Bogazici University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Peptide + novel adjuvant",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "InnoMedica": [
      {
         "Developer ": {
            " Researcher": "InnoMedica"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Protein subunit",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Protein subunit, TaliCoVax19 ",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Institut Pasteur / Themis / University of Pittsburgh / Merck": [
      {
         "Developer ": {
            " Researcher": "Institut Pasteur / Themis / University of Pittsburgh / Merck"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start animal testing in April 2020; clinical testing to start later in 2020",
         "Product Description": "Replicating viral vector; measles vector",
         "Clinical Trials for COVID-19": "",
         "Funder": "Coalition for Epidemic Preparedness (CEPI)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for West nile, CHIKV, Ebola, Lassa, Zika, MERS"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/28/2020"
      }
   ],
   "DZIF - German Center for Infection Research/ CanVirex AG": [
      {
         "Developer ": {
            " Researcher": "DZIF - German Center for Infection Research/ CanVirex AG"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Measles virus (S, N targets)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for Zika, H7N9, CHIKV"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      }
   ],
   "The Lancaster University, UK": [
      {
         "Developer ": {
            " Researcher": "The Lancaster University, UK"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Avian paramyxovirus vector (APMV)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/19/2020"
      }
   ],
   "IAVI/ Merck": [
      {
         "Developer ": {
            " Researcher": "IAVI/ Merck"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Will join US Operation Warp Speed vaccine trials; clinical studies to start in 2020",
         "Product Description": "Replicating viral vector, replication-competent VSV chimeric virus technology (VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for Ebola, Marburg, Lassa (including FDA-licensed Ebola vaccine, ERVEBO®)"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/4/2020"
      }
   ],
   "The University of Hong Kong": [
      {
         "Developer ": {
            " Researcher": "The University of Hong Kong"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Replicating viral vector, influenza vector expressing RBD",
         "Clinical Trials for COVID-19": "",
         "Funder": "Coalition for Epidemic Preparedness (CEPI)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for MERS"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "KU Leuven": [
      {
         "Developer ": {
            " Researcher": "KU Leuven"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Replicating viral vector; YF17D Vector",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "BIOCAD / IEM": [
      {
         "Developer ": {
            " Researcher": "BIOCAD / IEM"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.": [
      {
         "Developer ": {
            " Researcher": "Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ."
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/19/2020"
      }
   ],
   "University of Wisconsin-Madison / FluGen/ Bharat Biotech": [
      {
         "Developer ": {
            " Researcher": "University of Wisconsin-Madison / FluGen/ Bharat Biotech"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase I trial in fall 2020",
         "Product Description": "M2-deficient single replication (M2SR) influenza vector",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for influenza"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "Tonix Pharma / Southern Research": [
      {
         "Developer ": {
            " Researcher": "Tonix Pharma / Southern Research"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Replicating viral vector; horsepox vector expressing S protein; TNX-1800",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for smallpox, monkeypox"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/19/2020"
      }
   ],
   "University of Western Ontario": [
      {
         "Developer ": {
            " Researcher": "University of Western Ontario"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Replicating viral vector; VSV-S",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for HIV, MERS"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Fundacao Oswaldo Cruz and Instituto Buntantan": [
      {
         "Developer ": {
            " Researcher": "Fundacao Oswaldo Cruz and Instituto Buntantan"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Attenuated Influenza expressing an antigenic portion of the Spike protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/27/2020"
      }
   ],
   "Israel\n  Institute for Biological Research/ Weizmann Institute of Science": [
      {
         "Developer ": {
            " Researcher": "Israel\n  Institute for Biological Research/ Weizmann Institute of Science"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating viral vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "VSV-S ",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/23/2020"
      }
   ],
   "Fudan University / Shanghai JiaoTong University / RNACure Biopharma": [
      {
         "Developer ": {
            " Researcher": "Fudan University / Shanghai JiaoTong University / RNACure Biopharma"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RNA; LNP-encapsulated mRNA cocktail encoding VLP",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      },
      {
         "Developer ": {
            " Researcher": "Fudan University / Shanghai JiaoTong University / RNACure Biopharma"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RNA; LNP-encapsulated mRNA cocktail encoding RBD",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Greenlight Biosciences\n": [
      {
         "Developer ": {
            " Researcher": "Greenlight Biosciences\n"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "mRNA\n",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/12/2020"
      }
   ],
   "Moderna/ NIAID/ Lonza/ Catalent/ Rovi": [
      {
         "Developer ": {
            " Researcher": "Moderna/ NIAID/ Lonza/ Catalent/ Rovi"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Phase II",
         "Anticipated Next Steps": "Will join US Operation Warp Speed vaccine Phase III trials in July 2020; Completed enrollment for both cohorts of the Phase II study in early July 2020; FDA granted fast track designation May 2020",
         "Product Description": "RNA; LNP-encapsulated mRNA (mRNA 1273)",
         "Clinical Trials for COVID-19": "NCT04283461, NCT04405076",
         "Funder": "Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA)",
         "Published Results": "Moderna (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for multiple candidates"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/10/2020"
      }
   ],
   "CanSino Biologics/Precision Nanosystems": [
      {
         "Developer ": {
            " Researcher": "CanSino Biologics/Precision Nanosystems"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RNA; mRNA lipid nanoparticle (mRNA-LNP)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/21/2020"
      }
   ],
   "BIOCAD": [
      {
         "Developer ": {
            " Researcher": "BIOCAD"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Animal studies begin in April 2020",
         "Product Description": "RNA; liposome-encapsulated mRNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for cancer   "
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "GeneOne Life Science / Houston Methodist": [
      {
         "Developer ": {
            " Researcher": "GeneOne Life Science / Houston Methodist"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp": [
      {
         "Developer ": {
            " Researcher": "eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase I early 2021",
         "Product Description": "RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "China CDC / Tongji University / Stermina": [
      {
         "Developer ": {
            " Researcher": "China CDC / Tongji University / Stermina"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RNA; mRNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "University of Tokyo / Daiichi-Sankyo": [
      {
         "Developer ": {
            " Researcher": "University of Tokyo / Daiichi-Sankyo"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RNA; LNP-encapsulated mRNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for MERS"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Arcturus/Duke-NUS/ Catalent\n": [
      {
         "Developer ": {
            " Researcher": "Arcturus/Duke-NUS/ Catalent\n"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase I trial August 2020",
         "Product Description": "LUNAR-COV19; RNA; mRNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for multiple candidates"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "CureVac": [
      {
         "Developer ": {
            " Researcher": "CureVac"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Phase I",
         "Anticipated Next Steps": "Start Phase I/IIa trial June 2020",
         "Product Description": "RNA; mRNA",
         "Clinical Trials for COVID-19": "NCT04449276",
         "Funder": "Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA); German Government; European Investment Bank (EIB)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/10/2020"
      }
   ],
   "Imperial College London/ VacEquity Global Health": [
      {
         "Developer ": {
            " Researcher": "Imperial College London/ VacEquity Global Health"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Phase I",
         "Anticipated Next Steps": "Phase I/II trial started June 2020",
         "Product Description": "RNA; LNP-nCoVsaRNA",
         "Clinical Trials for COVID-19": "ISRCTN17072692",
         "Funder": "UK Government",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/10/2020"
      }
   ],
   "Sanofi Pasteur / Translate Bio": [
      {
         "Developer ": {
            " Researcher": "Sanofi Pasteur / Translate Bio"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start Q4 2020",
         "Product Description": "LNP-mRNA\n",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/24/2020"
      }
   ],
   "RNAimmune, Inc.": [
      {
         "Developer ": {
            " Researcher": "RNAimmune, Inc."
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RNA; several mRNA candidates",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "BioNTech/ Fosun Pharma/ Pfizer": [
      {
         "Developer ": {
            " Researcher": "BioNTech/ Fosun Pharma/ Pfizer"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Phase I",
         "Anticipated Next Steps": "FDA granted Fast Track designation for two BNT162 candidates (BNT162b1 and BNT162b2); Phase IIb/III trial may start as early as July 2020 (not participating in the NIH testing program); Phase I/II started April 2020; first data released July 1, 2020",
         "Product Description": "3 LNP-mRNAs; BNT162 \n",
         "Clinical Trials for COVID-19": "EudraCT 2020-001038-36, NCT04368728",
         "Funder": "Unknown",
         "Published Results": "Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing-0), medRxiv (https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/13/2020"
      }
   ],
   "Ziphius Therapeutics/ Ghent University": [
      {
         "Developer ": {
            " Researcher": "Ziphius Therapeutics/ Ghent University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/28/2020"
      }
   ],
   "Max Planck Institute of Colloids and Interfaces": [
      {
         "Developer ": {
            " Researcher": "Max Planck Institute of Colloids and Interfaces"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "mRNA in targeted LPNs (Langerhans cell specific)",
         "Clinical Trials for COVID-19": "",
         "Funder": "KHAN-1 Technology Transfer Fund I GmbH & Co KG",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/2/2020"
      }
   ],
   "Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious  Disease": [
      {
         "Developer ": {
            " Researcher": "Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious  Disease"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Self amplifying RNA, self-assembling delivery system",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "Chula Vaccine Research Center/University of Pennsylvania": [
      {
         "Developer ": {
            " Researcher": "Chula Vaccine Research Center/University of Pennsylvania"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "LNP-mRNA",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/26/2020"
      }
   ],
   "People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech": [
      {
         "Developer ": {
            " Researcher": "People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "RNA-based vaccine",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "mRNA",
         "Clinical Trials for COVID-19": "ChiCTR2000034112",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/10/2020"
      }
   ],
   "Medicago Inc.": [
      {
         "Developer ": {
            " Researcher": "Medicago Inc."
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase I in July/August 2020; Phase II by the end of 2020",
         "Product Description": "VLP; plant-derived VLP adjuvanted with GSK or Dynavax adjs.",
         "Clinical Trials for COVID-19": "NCT04450004",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "ARTES Biotechnology\n": [
      {
         "Developer ": {
            " Researcher": "ARTES Biotechnology\n"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "VLP; eVLP",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for malaria\n"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/4/2020"
      }
   ],
   "University of Sao Paulo": [
      {
         "Developer ": {
            " Researcher": "University of Sao Paulo"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "VLPs peptides/whole virus",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/19/2020"
      }
   ],
   "VBI Vaccines / National Research Council of Canada": [
      {
         "Developer ": {
            " Researcher": "VBI Vaccines / National Research Council of Canada"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase I testing by end of 2020",
         "Product Description": "Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      }
   ],
   "Saiba GmbH": [
      {
         "Developer ": {
            " Researcher": "Saiba GmbH"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "VLP; virus-like particle, based on RBD displayed on virus-like particle",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Doherty Institute": [
      {
         "Developer ": {
            " Researcher": "Doherty Institute"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "VLP; unknown",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/8/2020"
      }
   ],
   "Imophoron Ltd / Bristol University's Max Planck Centre": [
      {
         "Developer ": {
            " Researcher": "Imophoron Ltd / Bristol University's Max Planck Centre"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "VLP; ADDomerTM multiepitope display",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "OSIVAX": [
      {
         "Developer ": {
            " Researcher": "OSIVAX"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "VLP (COVID-19 and SARS1)",
         "Clinical Trials for COVID-19": "",
         "Funder": "European Innovation Council (EIC)",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj Hospital": [
      {
         "Developer ": {
            " Researcher": "Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj Hospital"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "VLP + Adjuvant",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      }
   ],
   "Navarrabiomed, Oncoimmunology group": [
      {
         "Developer ": {
            " Researcher": "Navarrabiomed, Oncoimmunology group"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Virus-like particles, lentivirus, and baculovirus vehicles",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/1/2020"
      }
   ],
   "IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols": [
      {
         "Developer ": {
            " Researcher": "IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "S protein integrated in HIV VLPs",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/23/2020"
      }
   ],
   "Middle East Technical University": [
      {
         "Developer ": {
            " Researcher": "Middle East Technical University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "VLP",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/9/2020"
      }
   ],
   "Medicago Inc./ Dynavax": [
      {
         "Developer ": {
            " Researcher": "Medicago Inc./ Dynavax"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start mid-July 2020",
         "Product Description": "VLP (CoVLP)+ Adjuvant (CpG 1018)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/10/2020"
      }
   ],
   "Medicago\n  Inc./ GSK": [
      {
         "Developer ": {
            " Researcher": "Medicago\n  Inc./ GSK"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Virus-like particle",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "VLP (CoVLP)+ Adjuvant",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "7/14/2020"
      }
   ],
   "Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile": [
      {
         "Developer ": {
            " Researcher": "Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Unknown",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/23/2020"
      }
   ],
   "Tulane University": [
      {
         "Developer ": {
            " Researcher": "Tulane University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Unknown",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Shenzhen Geno-Immune Medical Institute": [
      {
         "Developer ": {
            " Researcher": "Shenzhen Geno-Immune Medical Institute"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins",
         "Clinical Trials for COVID-19": "NCT04299724",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/12/2020"
      },
      {
         "Developer ": {
            " Researcher": "Shenzhen Geno-Immune Medical Institute"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes",
         "Clinical Trials for COVID-19": "NCT04276896",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/12/2020"
      }
   ],
   "Covaxx": [
      {
         "Developer ": {
            " Researcher": "Covaxx"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I to start in summer 2020",
         "Product Description": "Unknown",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/21/2020"
      }
   ],
   "HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital": [
      {
         "Developer ": {
            " Researcher": "HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Animal study results by October 2020",
         "Product Description": "Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Analog Devices Foundation",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/21/2020"
      }
   ],
   "SmartPharm Therapeutics / Sorrento Therapeutics": [
      {
         "Developer ": {
            " Researcher": "SmartPharm Therapeutics / Sorrento Therapeutics"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Gene-encoded antibody vaccine, non-viral nanoparticle delivery",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID)": [
      {
         "Developer ": {
            " Researcher": "Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID)"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Unknown",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "4/24/2020"
      }
   ],
   "AbVision": [
      {
         "Developer ": {
            " Researcher": "AbVision"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "AVI-205",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/13/2020"
      }
   ],
   "SK Biosciences": [
      {
         "Developer ": {
            " Researcher": "SK Biosciences"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Phase I begins as early as September 2020",
         "Product Description": "Unknown",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Precision Vaccines Program at Boston Children's Hospital": [
      {
         "Developer ": {
            " Researcher": "Precision Vaccines Program at Boston Children's Hospital"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Unknown",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Oragenics (Noachis Terra)/ Aragen Bioscience\n": [
      {
         "Developer ": {
            " Researcher": "Oragenics (Noachis Terra)/ Aragen Bioscience\n"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Start Phase I in late 2020 or early 2021",
         "Product Description": "TerraCoV2\n",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/21/2020"
      }
   ],
   "Vivaldi Biosciences/ Esco Aster Pte Ltd": [
      {
         "Developer ": {
            " Researcher": "Vivaldi Biosciences/ Esco Aster Pte Ltd"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Chimeric vaccine (coronavirus and influenza)",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/2/2020"
      }
   ],
   "Adeleke University": [
      {
         "Developer ": {
            " Researcher": "Adeleke University"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Unknown",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/30/2020"
      }
   ],
   "Codiak BioSciences/ Ragon Institute": [
      {
         "Developer ": {
            " Researcher": "Codiak BioSciences/ Ragon Institute"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "exoVACC exome platform",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/4/2020"
      }
   ],
   "Vault Pharma/ University of California Los Angeles": [
      {
         "Developer ": {
            " Researcher": "Vault Pharma/ University of California Los Angeles"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "nanoparticles (vaults) as second-line defense of infection",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/17/2020"
      }
   ],
   "NidoVax": [
      {
         "Developer ": {
            " Researcher": "NidoVax"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Unknown",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "unknown; IMT504 technology",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "6/18/2020"
      }
   ],
   "University of California, Los Angeles (Horwitz Lab)": [
      {
         "Developer ": {
            " Researcher": "University of California, Los Angeles (Horwitz Lab)"
         },
         "Treatment vs. Vaccine": "Vaccine",
         "Product Category": "Replicating bacterial vector",
         "Stage of Development": "Pre-clinical",
         "Anticipated Next Steps": "Unknown",
         "Product Description": "Recombinant LVS ΔcapB – vectored vaccine expressing multiple SARS-CoV-2 antigens",
         "Clinical Trials for COVID-19": "",
         "Funder": "Unknown",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": "Same platform as vaccines against select agents and emerging pathogens"
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/10/2020"
      }
   ],
   "The First Affiliated Hospital of Guangzhou Medical University": [
      {
         "Developer ": {
            " Researcher": "The First Affiliated Hospital of Guangzhou Medical University"
         },
         "Treatment vs. Vaccine": "Dormant / Discontinued",
         "Product Category": "Dormant / Discontinued",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "",
         "Product Description": "Recombinant ACE2 (angiotensin-converting enzyme 2)",
         "Clinical Trials for COVID-19": "NCT04287686 ",
         "Funder": "",
         "Published Results": "Study stopped before recruitment",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "Unknown",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "The Second Hospital of Nanjing Medical University": [
      {
         "Developer ": {
            " Researcher": "The Second Hospital of Nanjing Medical University"
         },
         "Treatment vs. Vaccine": "Dormant / Discontinued",
         "Product Category": "Dormant / Discontinued",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "",
         "Product Description": "Washed microbiota transplantation",
         "Clinical Trials for COVID-19": "NCT04251767",
         "Funder": "",
         "Published Results": "Study stopped before recruitment",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "Unknown",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "Prior to 4/20/2020"
      }
   ],
   "Mianyang Central Hospital \n": [
      {
         "Developer ": {
            " Researcher": "Mianyang Central Hospital \n"
         },
         "Treatment vs. Vaccine": "Dormant / Discontinued",
         "Product Category": "Dormant / Discontinued",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Chinese trial site last updated March 30, 2020\n",
         "Product Description": "Combination of ebastine, lopinavir, and interferon alpha\n",
         "Clinical Trials for COVID-19": "ChiCTR2000030535",
         "Funder": "",
         "Published Results": "",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "N/A",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/7/2020"
      }
   ],
   "Roche/the First Hospital Affiliated to Zhejiang University's Medical School\n": [
      {
         "Developer ": {
            " Researcher": "Roche/the First Hospital Affiliated to Zhejiang University's Medical School\n"
         },
         "Treatment vs. Vaccine": "Dormant / Discontinued",
         "Product Category": "Dormant / Discontinued",
         "Stage of Development": "Clinical",
         "Anticipated Next Steps": "Chinese trial site last updated February 12, 2020 \n",
         "Product Description": "Xofluza (baloxavir marboxil), polymerase acidic endonuclease inhibitor\n",
         "Clinical Trials for COVID-19": "ChiCTR2000029544\n\nChiCTR2000029548",
         "Funder": "",
         "Published Results": "medRxiv (https://doi.org/10.1101/2020.04.29.20085761) (ChiCTR2000029544)",
         "Clinical Trials for Other Diseases (T only) ": {
            " Related Use or Platform (V only)": ""
         },
         "FDA-Approved Indications": "FDA-approved since 2018, approved to treat influenza\n",
         "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
         "Date Last Updated": "5/10/2020"
      }
   ]
}